Ascaroside derivatives and methods of use
By developing a compound with the structure of formula (I), the shortcomings in the treatment of inflammatory diseases and autoimmune diseases in the prior art are solved, and effective treatment of inflammatory diseases is achieved by inhibiting IL-6 and IL-1β secretion.
Patent Information
- Application Number
- CN202080050902.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-17
- Filing Date
- 2020-05-15
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-05-15
AI Technical Summary
The existing parasitic nematode-related treatment methods have not improved enough for inflammatory and autoimmune diseases, and it is difficult to effectively regulate the immune response.
A compound with the structure of formula (I) was developed for the treatment of inflammatory and autoimmune diseases by inhibiting the secretion of IL-6 and IL-1β, including the use of the compound as a pharmaceutical preparation to reduce the subject's Inflammatory cytokine release and cell activation.
It significantly reduces inflammatory cytokine release and effectively treats inflammatory and autoimmune diseases, especially IL-6 and IL-1β-mediated diseases, providing a new therapeutic approach.
Smart Images

Figure BDA0003467668240000021 
Figure BDA0003467668240000023 
Figure BDA0003467668240000031
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 849,387, filed May 17, 2019, the entire contents of which are incorporated herein by reference.
[0003] Joint ownership under 35 U.S.C. 102(c) of a joint research agreement
[0004] The subject matter disclosed in this application was developed by or on behalf of one or more parties to a joint research agreement and the claimed invention was made by or on behalf of one or more parties to a joint research agreement that was in effect on or before the effective filing date of the claimed invention. The parties to the joint research agreement are as follows: California Institute of Technology and Holoclara, Inc.
[0005] background
[0006] Many nematode species are known to parasitize humans; this relationship is thought to have existed for thousands of years.
[0007] An inverse relationship exists between areas where parasitic nematodes are endemic and areas where autoimmune diseases are prevalent. This observation has inspired the hypothesis that parasitic nematodes or nematode-derived secretions can protect against autoimmune diseases, and this has been confirmed in many human clinical trials and animal model studies, in which administration of parasitic nematodes has reduced disease symptoms.
[0008] Several nematode-based approaches have been identified for the treatment of autoimmune and inflammatory diseases. However, there is a need for improved treatments compared to agents and / or isolates of parasitic nematodes.
[0009] Overview
[0010] In one aspect, provided herein are compounds having the structure of Formula (I):
[0011]
[0012] in
[0013] Ring D is selected from
[0014] represents the point of attachment of ring D to the oxygen atom;
[0015] X is -C(R 5 )2-C(R 5 )2- or E or Z-CH=CH-;
[0016] Y is O or NR 6 ;
[0017] R is H or CH3,
[0018] R 1 is H or CH3;
[0019] Or, R and R 1 Together with the carbon atoms to which they are bonded, they form a 3- or 4-membered carbocyclic ring;
[0020] R 2 is H or CH3;
[0021] R 3 is H or CH3;
[0022] R 4 is CH3, CH2CH3, a linear or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, a C1-C6 alkyl group substituted with an aryl group, or a C1-C6 alkyl group substituted with a heterocyclic group;
[0023] R 5 Each occurrence is independently H or OH,
[0024] or two R 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring; and
[0025] R 6 is H or C1-C6 alkyl,
[0026] Or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bonded, they form a 5- or 6-membered heterocyclic ring.
[0027] In another aspect, provided herein is a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a compound having a structure of formula (I):
[0028]
[0029] In another aspect, provided herein is a method of treating a disease or condition in a subject in need thereof, the method comprising:
[0030] administering to a subject an effective amount of a compound having the structure of formula (I),
[0031]
[0032] The disease or disorder is an inflammatory disease, an autoimmune disease, or both.
[0033] Other features and advantages of the present invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings, which illustrate by way of example various embodiments of the invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Example embodiments are illustrated in the noted drawings. It is intended that the embodiments and figures disclosed in this application be regarded as illustrative rather than restrictive.
[0036] Figure 1A Compound 1 was shown to reduce the amount of IL-6 released by THP-1 derived macrophages 72 hours after stimulation in an in vitro assay.
[0037] Figure 1B Compound 10 was shown to reduce the amount of IL-6 released by THP-1 derived macrophages 72 hours after stimulation in an in vitro assay.
[0038] Figure 2A Compound 1 was shown to reduce the amount of IL-6 released by THP-1 derived macrophages 72 hours after stimulation in vitro, more than ascr#7.
[0039] Figure 2B Compound 10 was shown to reduce the amount of IL-6 released by THP-1 derived macrophages 72 hours after stimulation in vitro, more than ascr#7.
[0040] Figure 3A Compound 1 was shown to reduce the amount of TNFα released by THP-1 derived macrophages 72 hours after stimulation in an in vitro assay.
[0041] Figure 3B Compound 10 was shown to reduce the amount of TNFα released by THP-1 derived macrophages 72 hours after stimulation in an in vitro assay.
[0042] Figure 4 Shown are the half-lives of ascr#7 in mouse, rat, and human hepatocytes and the half-life of compound 1 in rat hepatocytes and human hepatocytes.
[0043] Figure 5A The clearance rates of ascr#7 in rat plasma and human plasma and the clearance rates of compound 1 in rat plasma and human plasma are shown.
[0044] Figure 5B The clearance rate of ascr#7 in mouse plasma is shown.
[0045] Figure 6 The bidirectional permeability of ascr#7 in CaCo-2 cells and the bidirectional permeability of compound 1 in CaCo-2 cells were shown.
[0046] Figure 7The extent of plasma protein binding of ascr#7 and compound 1 is shown.
[0047] Figure 8 Inhibition of cytochrome P450 isoforms by ascr#7 and compound 1 in a CYP inhibition assay is shown.
[0048] Fig. 9 Compounds 1, 2, 3, 5, 6, 8, 9, 10, 11 and 13 inhibited IL-6 in a statistically significant dose-dependent manner in human macrophages (THP-1).
[0049] Fig. 10A Compound 1 inhibits IL1β-induced production of multiple inflammatory cytokines (IL-6, IL-8, IL-25, IL-33) in human lung epithelial cells (BEAS-2B).
[0050] Fig. 10B Compound 1 inhibits IL1β-induced production of multiple inflammatory cytokines (eotaxin, GMCSF, MCP-1, TSLP) in human lung epithelial cells (BEAS-2B).
[0051] Fig.11A Compound 1 inhibits IL1β-induced production of multiple inflammatory cytokines (IL-6, IL-8, IL-25, IL-33) in human lung epithelial cells (BEAS-2B).
[0052] Fig. 11B Compound 1 inhibits LPS-induced production of multiple inflammatory cytokines (GMCSF, MCP-1, TSLP) in human lung epithelial cells (BEAS-2B).
[0053] Fig.12 Compound 6 inhibited IL1β-induced production of multiple inflammatory cytokines (IL-25, IL-33, eosinophil activation chemokines, TSLP) in human lung epithelial cells (BEAS-2B).
[0054] Fig.13 Compound 2 inhibits IL1β-induced eotaxin inflammatory cytokine in human lung epithelial cells (BEAS-2B).
[0055] Fig.14 Compound 1 inhibited multiple inflammatory cytokines (IL-5, IFNγ, TGFβ) in a statistically significant dose-dependent manner in human T cells.
[0056] Fig.15 Compounds 3 and 4 inhibited inflammatory cytokines (IL-6, IL-8, TNFα) in human T cells.
[0057] Fig.16 Compound 1 inhibits multiple inflammatory cytokines (IL-8, IL-25, IL-33, MCP-1, GM-CSF) in human alveolar epithelial cells (A549).
[0058] Fig.17 Compound 10 inhibited multiple inflammatory cytokines (IL-25, IL-33, MCP-1, GM-CSF) in human alveolar epithelial cells (A549).
[0059] Fig.18 Compounds 1 and 10 inhibited multiple inflammatory cytokines (eotaxin, IL-6, RANTES, TSLP) in human alveolar epithelial cells (A549).
[0060] Fig.19A Compounds 1, 3, 4, 10 and 13 inhibited TSLP expression in human primary esophageal keratinocytes (EPC2) in a statistically significant manner.
[0061] Fig.19B Compounds 1, 2, 3, 4 and 10 inhibited IL6 expression in human primary esophageal keratinocytes (EPC2) in a statistically significant manner.
[0062] Fig.19C Compounds 1, 2, 3, 4, 10, 11 and 13 inhibited MCP-1 expression in human primary esophageal keratinocytes (EPC2) in a statistically significant manner.
[0063] Fig. 20 Schematic timeline of L2-IL5 transgenic mice sensitized / topically challenged with oxazolone antigen - an in vivo model of eosinophilic esophagitis.
[0064] Fig.21 NDM-X and Compound 1 inhibited the in vivo model of eosinophilic esophagitis in L2-IL5 transgenic mice sensitized / topically challenged with oxazolone antigen.
[0065] Fig. 22 NDM-X and Compound 1 inhibited the in vivo model of eosinophilic esophagitis in L2-IL5 transgenic mice sensitized / topically challenged with oxazolone antigen.
[0066] Fig.23 Compound 1 inhibits the in vivo model of eosinophilic esophagitis in L2-IL5 transgenic mice sensitized / topically challenged with oxazolone antigen.
[0067] Fig.24 NDM-X inhibits an in vivo model of eosinophilic esophagitis in L2-IL5 transgenic mice sensitized / topically challenged with oxazolone antigen.
[0068] Detailed Description
[0069] Overview
[0070] The present invention is based, at least in part, on the discovery that ascarosides, a family of small molecule nematode pheromones, modulate immune responses and have therapeutic effects on various autoimmune and inflammatory diseases. One of the ascaroside derivatives, a compound of formula (I) or (II), significantly inhibits hallmark pathological phenomena in mouse models of asthma, inflammatory bowel disease, and type 1 diabetes and significantly reduces IL-6 and IL-1β secretion. These findings suggest that the compounds have therapeutic effects on diseases in which elevated levels of IL-6 and / or IL-1β contribute to disease pathogenesis.
[0071] In some aspects, the present invention provides a method of treating an inflammatory disease, an autoimmune disease, or both in a subject. The method comprises administering to the subject an effective amount of a compound having a structure of formula (I) or (II).
[0072] In some embodiments, the subject has elevated levels of IL-6, IL-1β and / or TNFα (also referred to herein as TNF-α). In certain embodiments, IL-6, IL-1β and / or TNFα contribute to one or more symptoms of the disease. In embodiments such as these, the method may include assessing the level of IL-6, IL-1β and / or TNFα in the affected tissue of the subject, and if the level exceeds 200% of the normal level for the affected tissue, a compound of formula (I) or (II) is administered.
[0073] Thus, the present invention relates in part to methods for treating an inflammatory disease, an autoimmune disease, or both in a subject. In some embodiments, the present invention relates to methods for treating an IL-6, IL-1β, and / or TNFα-mediated disease in a subject by administering a compound of formula (I) to the subject. In other aspects, the present invention relates to methods for reducing the production of IL-6 and / or IL-1β from a cell by contacting the cell or associated cell with a compound of formula (I) or (II).
[0074] definition
[0075] Unless defined otherwise, technical and scientific terms used in this application have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 3rd Edition, J. Wiley & Sons (New York, NY 2001); March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 5th Edition, J. Wiley & Sons (New York, NY 2001); and Sambrook and Russel, Molecular Cloning: A Laboratory Manual 3rd Edition, Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY 2001) provide one of ordinary skill in the art with a general guide to many of the terms used in this application.
[0076] Those skilled in the art will recognize many methods and materials that are similar to or equivalent to the methods and materials described in this application, which can be used to implement the present invention. In fact, the present invention is in no way limited to the methods and materials. For purposes of the present invention, the following terms are defined as follows.
[0077] As used in this application, unless otherwise indicated, the following terms shall be understood to have the following meanings. Unless otherwise defined in this application, all technical and scientific terms used in this application have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. In the event that a term has multiple definitions in this application, the definition in this section shall prevail unless otherwise indicated.
[0078] The term "compound of the invention" and equivalent expressions thereof are meant to encompass the compound as described, as well as any stereoisomeric form or mixtures of any such forms of the compound in any proportion, unless otherwise specifically stated. Inclusion complexes are described in Remington, The Science and Practice of Pharmacy, 19th ed., 1:176-177 (1995), the entire contents of which are incorporated herein by reference. The most commonly used inclusion complexes are those with cyclodextrins and all natural and synthetic cyclodextrin complexes are specifically included in the claims. For clarity, specific examples are sometimes shown in the text when the context so permits, but these examples are purely illustrative and are not intended to exclude other examples when the context so permits.
[0079] Many compounds useful in the methods and compositions of the present disclosure have at least one stereogenic center in their structure. This stereogenic center may exist in the R or S configuration, with the R and S symbols being used in accordance with the rules described in Pure Appl. Chem. (1976), 45, 11–30. The present disclosure contemplates all stereoisomeric forms of the compounds, such as enantiomeric and diastereomeric forms, salts, prodrugs, or mixtures thereof (including all possible stereoisomeric mixtures). See, for example, WO 01 / 062726.
[0080] Additionally, certain compounds containing alkenyl groups may exist as Z (zusammen) or E (entgegen) isomers. In each instance, the disclosure includes both the mixture and the individual isomers.
[0081] Some of the compounds may also exist in tautomeric forms. Although not explicitly shown in the formulae described in this application, such forms are intended to be included within the scope of the present disclosure.
[0082] In some embodiments, the compound of formula (I) or (II) is enantiomerically enriched at the side chain methyl group stereogenic center. The level of enantiomeric enrichment of the compound can be expressed as enantiomeric excess (ee). The ee of the compound can be determined by dividing the difference between the enantiomeric scores by the sum of the enantiomeric scores. For example, if the compound is found to contain 98% (S)-enantiomer and 2% (R)-enantiomer, the ee of the compound is (98-2) / (98+2), or 96%. In certain embodiments, the compound of formula (I) has about 5% ee or greater, 10% ee or greater, 15% ee or greater, 20% ee or greater, 25% ee or greater, 30% ee or greater, 40% ee or greater, 50% ee or greater, 60% ee or greater, 70% ee or greater, about 80% ee, about 85% ee, about 88% ee, about 90% ee, about 91% ee, about 92% ee, about 93% ee, about 94% ee, about 95% ee, about 96% ee, about 97% ee, about 98% ee, about 99% ee or greater than about 99% ee, even wherein the % ee is greater than the % ee of the starting material, such as 0% ee (racemate). In some embodiments, the compound of formula (I) or (II) is an enantiomerically enriched compound. In some embodiments, the compound of formula (I) or (II) is a pure enantiomer, for example, having the structure of compound 1 or 10. In embodiments where the starting material has more than one stereocenter, the disclosed reactions can be enriched in the stereocenter bearing the methyl group (relative to the enrichment of that center of the starting material, if any), and are substantially independent of the stereochemical arrangement / enrichment (de) of any other stereocenter of the molecule. For example, the compounds of formula (I) or (II) described herein can have 5% de or greater, 10% de or greater, 15% de or greater, 20% de or greater, 25% de or greater, 30% de or greater, 40% de or greater, 50% de or greater, 60% de or greater, 70% de or greater, 80% de or greater, 90% de or greater, 95% de or greater, or even 98% de or greater at the stereocenter of the compound of formula (I) bearing the methyl group.
[0083] As used in this application, the term "ascr#7" refers to the compound,
[0084] It is also referred to as NDM-X in this application.
[0085] or a pharmaceutically acceptable salt thereof.
[0086] Compound
[0087] In one aspect, provided herein are compounds having the structure of Formula (I):
[0088]
[0089] in
[0090] Ring D is selected from
[0091] represents the point of attachment of ring D to the oxygen atom;
[0092] X is -C(R 5 )2-C(R 5 )2- or E or Z-CH=CH-;
[0093] Y is O or NR 6 ;
[0094] R is H or CH3;
[0095] R 1 is H or CH3;
[0096] Or, R and R 1 Together with the carbon atoms to which they are bonded, they form a 3- or 4-membered carbocyclic ring;
[0097] R 2 is H or CH3;
[0098] R 3 is H or CH3;
[0099] R 4 is CH3, CH2CH3, a linear or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, a C1-C6 alkyl group substituted with an aryl group, or a C1-C6 alkyl group substituted with a heterocyclic group;
[0100] R 5 Each occurrence is independently H or OH,
[0101] or two R 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring; and
[0102] R 6 is H or C1-C6 alkyl,
[0103] Or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bonded, they form a 5- or 6-membered heterocyclic ring.
[0104] In some embodiments, the compound of formula (I) is selected from
[0105] In some embodiments, X is -C(R 5 )2-C(R 5 )2-. In some embodiments, X is E or Z-CH=CH-. In some embodiments, X is -C(H)2-C(H)2-. In some embodiments, X is -C(H)(OH)-C(H)2-.
[0106] In some embodiments, XC(R 5 )2-C(R 5 )2-, two R 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring. In some embodiments, X is In some embodiments, X is In some embodiments, X is In some embodiments, X is
[0107] In some embodiments, Y is NR 6 In some embodiments, Y is NR 6 , where R 6 is H. In some embodiments, Y is NR 6 , where R 6 is C1-C6 alkyl. In some embodiments, Y is NR 6 , where R 6 In some embodiments, Y is NR 6 , where R 6 In some embodiments, Y is NR 6 , where R 4 and NR 6 Together with the carbon atoms to which they are bound, they form a 5- or 6-membered heterocyclic ring.
[0108] In some embodiments, R and R 1 Each is CH3. In some embodiments, R and R 1 Each is CH3. In some embodiments, R is CH3; and R 1 is H. In some embodiments, R and R 1 Together with the carbon atom to which they are bonded, they form a cyclopropyl group. 1 Together with the carbon atom to which they are bonded they form a cyclobutyl group.
[0109] In some embodiments, R 2 H; R 3 is H or CH3; and R 4is CH3, CH2CH3, a straight or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, an aryl-substituted C1-C6 alkyl group or a heterocyclic-substituted C1-C6 alkyl group, or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bound, they form a 5-membered or 6-membered heterocyclic ring. 2 , R 3 and R 4 Each is CH3. In some embodiments, R 2 H; R 3 is CH3; and R 4 is CH3. In some embodiments, R 2 H; R 3 is H; and R 4 is CH2CH3. In some embodiments, R 2 H; R 3 is H; and R 4 is CH(CH2CH3)2. In some embodiments, R 2 H; R 3 is H; and R 4 is CH(CH2CH3)2. In some embodiments, R 2 H; R 3 is H; and R 4 In some embodiments, R 2 H; R 3 is H; and R 4 In some embodiments, R 2 H; R 3 is H; and R 4 It is pyridyl.
[0110] In some embodiments, the compound of formula (I) is selected from
[0111]
[0112]
[0113]
[0114] In some embodiments, the compound of formula (I) is selected from
[0115]
[0116]
[0117] In one aspect, provided herein is a compound of formula (II) having the following structural formula:
[0118]
[0119] in
[0120] Ring D is selected from
[0121] represents the point of attachment of ring D to the oxygen atom; and
[0122] A double bond or a single bond.
[0123] In some embodiments, the compound of formula (II) is a compound having the following structural formula:
[0124]
[0125] In some embodiments, the compound of formula (II) is a compound having the following structural formula:
[0126]
[0127] In some embodiments, the compound of formula (II) is selected from
[0128]
[0129] In certain embodiments, Ring D is
[0130]
[0131] In certain embodiments, Ring D is
[0132] in express mixture.
[0133] In certain embodiments, Ring D is
[0134] in express
[0135] In some embodiments, For double bonds.
[0136] In some embodiments, the stereochemistry at the carbon where the methyl group is substituted is R.
[0137] In some embodiments, is a double bond; and the stereochemistry at the carbon substituted with the methyl group is R.
[0138] method
[0139] In another aspect, the present application provides a method for reducing the proliferation or activation of macrophages, T cells, B cells, neutrophils, eosinophils, basophils or lymphocytes or a combination thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound having the structure of formula (I):
[0140]
[0141] in
[0142] Ring D is selected from
[0143] represents the point of attachment of ring D to the oxygen atom;
[0144] X is -C(R 5 )2-C(R 5 )2- or E or Z-CH=CH-;
[0145] Y is O or NR 6 ;
[0146] R is H or CH3;
[0147] R 1 is H or CH3;
[0148] Or, R and R 1 Together with the carbon atoms to which they are bonded, they form a 3- or 4-membered carbocyclic ring;
[0149] R 2 is H or CH3;
[0150] R 3 is H or CH3;
[0151] R 4 is CH3, CH2CH3, a linear or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, a C1-C6 alkyl group substituted with an aryl group, or a C1-C6 alkyl group substituted with a heterocyclic group;
[0152] R 5 Each occurrence is independently H or OH,
[0153] or two R 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring; and
[0154] R 6is H or C1-C6 alkyl,
[0155] Or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bonded, they form a 5- or 6-membered heterocyclic ring;
[0156] Thereby reducing the proliferation or activation of macrophages, T cells, B cells, neutrophils, eosinophils, basophils, lymphocytes or a combination thereof in the subject.
[0157] In some embodiments of the methods disclosed in this application, the compound of formula (I) is selected from
[0158] In some embodiments of the methods disclosed herein, X is -C(R 5 )2-C(R 5 )2-. In some embodiments, X is E or Z-CH=CH-. In some embodiments, X is -C(H)2-C(H)2-. In some embodiments, X is -C(H)(OH)-C(H)2-.
[0159] In some embodiments, XC(R 5 )2-C(R 5 2. Two Rs 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring. In some embodiments, X is In some embodiments, X is In some embodiments, X is In some embodiments, X is In some embodiments, X is In some embodiments of the methods disclosed herein, Y is NR 6 In some embodiments, Y is NR 6 , where R 6 is H. In some embodiments, Y is NR 6 , where R 6 is C1-C6 alkyl. In some embodiments, Y is NR 6 , where R 6 In some embodiments, Y is NR 6 , where R 6 In some embodiments, Y is NR 6 , where R 4 and NR 6 Together with the carbon atoms to which they are bound, they form a 5- or 6-membered heterocyclic ring.
[0160] In some embodiments of the methods disclosed in this application, R and R 1 Each is CH3. In some embodiments, R and R 1 Each is CH3. In some embodiments, R is CH3; and R 1 is H. In some embodiments, R and R 1 Together with the carbon atom to which they are bonded, they form a cyclopropyl group. 1 Together with the carbon atom to which they are bonded they form a cyclobutyl group.
[0161] In some embodiments of the methods disclosed in this application, R 2 H; R 3 is H or CH3; and R 4 is CH3, CH2CH3, a straight or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, an aryl-substituted C1-C6 alkyl group or a heterocyclic-substituted C1-C6 alkyl group, or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bound, they form a 5-membered or 6-membered heterocyclic ring. 2 , R 3 and R 4 Each is CH3. In some embodiments, R 2 H; R 3 is CH3; and R 4 is CH3. In some embodiments, R 2 H; R 3 is H; and R 4 is CH2CH3. In some embodiments, R 2 H; R 3 is H; and R 4 is CH(CH2CH3)2. In some embodiments, R 2 H; R 3 is H; and R 4 is CH(CH2CH3)2. In some embodiments, R 2 H; R 3 is H; and R 4 In some embodiments, R 2 H; R 3 is H; and R 4 In some embodiments, R 2 H; R 3 is H; and R 4 It is pyridyl.
[0162] In another aspect, provided herein is a method for reducing proliferation or activation of macrophages, T cells, B cells, neutrophils, eosinophils, basophils or lymphocytes or a combination thereof in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound having the structure of formula (II):
[0163]
[0164] in
[0165] Ring D is selected from
[0166] represents the point of attachment of ring D to the oxygen atom; and
[0167] is a double bond or a single bond;
[0168] The proliferation or activation of macrophages, T cells, B cells, neutrophils, eosinophils, basophils or lymphocytes, or a combination thereof, in the subject is thereby reduced.
[0169] In some embodiments of the methods disclosed in the present application, the compound of formula (II) is a compound having the following structure:
[0170]
[0171] In some embodiments of the methods disclosed in the present application, the compound of formula (II) is a compound having the following structure:
[0172]
[0173] In some embodiments of the methods disclosed in the present application, the compound of formula (II) is a compound selected from the following:
[0174]
[0175] In another aspect, provided herein is a method of treating a disease or condition in a subject in need thereof, the method comprising
[0176] administering to the subject an effective amount of a compound having the structure of formula (I),
[0177]
[0178] in
[0179] Ring D is selected from
[0180] represents the point of attachment of ring D to the oxygen atom;
[0181] X is -C(R 5 )2-C(R 5 )2- or E or Z-CH=CH-;
[0182] Y is O or NR 6 ;
[0183] R is H or CH3,
[0184] R 1 is H or CH3;
[0185] Or, R and R 1 Together with the carbon atoms to which they are bonded, they form a 3- or 4-membered carbocyclic ring;
[0186] R 2 is H or CH3;
[0187] R 3 is H or CH3;
[0188] R 4 is CH3, CH2CH3, a linear or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, a C1-C6 alkyl group substituted with an aryl group, or a C1-C6 alkyl group substituted with a heterocyclic group;
[0189] R 5 Each occurrence is independently H or OH,
[0190] or two R 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring; and
[0191] R 6 is H or C1-C6 alkyl,
[0192] Or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bonded, they form a 5- or 6-membered heterocyclic ring; and
[0193] The disease or disorder is an inflammatory disease, an autoimmune disease, or both.
[0194] In some embodiments of the methods disclosed in this application, the compound of formula (I) is selected from
[0195]
[0196]
[0197] In some embodiments of the methods disclosed herein, X is -C(R 5 )2-C(R 5 )2-. In some embodiments, X is E or Z-CH=CH-. In some embodiments, X is -C(H)2-C(H)2-. In some embodiments, X is -C(H)(OH)-C(H)2-.
[0198] In some embodiments, XC(R 5 )2-C(R 5 2. Two Rs 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring. In some embodiments, X is In some embodiments, X is In some embodiments, X is In some embodiments, X is
[0199] In some embodiments of the methods disclosed herein, Y is NR 6 In some embodiments, Y is NR 6 , where R 6 is H. In some embodiments, Y is NR 6 , where R 6 is C1-C6 alkyl. In some embodiments, Y is NR 6 , where R 6 In some embodiments, Y is NR 6 , where R 6 In some embodiments, Y is NR 6 , where R 4 and NR 6 Together with the carbon atoms to which they are bound, they form a 5- or 6-membered heterocyclic ring.
[0200] In some embodiments of the methods disclosed in this application, R and R 1 Each is CH3. In some embodiments, R and R 1 Each is CH3. In some embodiments, R is CH3; and R 1 is H. In some embodiments, R and R 1 Together with the carbon atom to which they are bonded, they form a cyclopropyl group. 1 Together with the carbon atom to which they are bonded they form a cyclobutyl group.
[0201] In some embodiments of the methods disclosed in this application, R 2H; R 3 is H or CH3; and R 4 is CH3, CH2CH3, a straight or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, an aryl-substituted C1-C6 alkyl group or a heterocyclic-substituted C1-C6 alkyl group, or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bound, they form a 5-membered or 6-membered heterocyclic ring. 2 , R 3 and R 4 Each is CH3. In some embodiments, R 2 H; R 3 is CH3; and R 4 is CH3. In some embodiments, R 2 H; R 3 is H; and R 4 is CH2CH3. In some embodiments, R 2 H; R 3 is H; and R 4 is CH(CH2CH3)2. In some embodiments, R 2 H; R 3 is H; and R 4 is CH(CH2CH3)2. In some embodiments, R 2 H; R 3 is H; and R 4 In some embodiments, R 2 H; R 3 is H; and R 4 In some embodiments, R 2 H; R 3 is H; and R 4 It is pyridyl.
[0202] In another aspect, provided herein is a method of treating a disease or condition in a subject in need thereof, the method comprising
[0203] An effective amount of a compound having the structure of Formula (II) is administered to the subject:
[0204]
[0205] in
[0206] Ring D is selected from
[0207] represents the point of attachment of ring D to the oxygen atom; and
[0208] is a double bond or a single bond; and
[0209] The disease or disorder is an inflammatory disease, an autoimmune disease, or both.
[0210] In certain embodiments, the disease is an IL-6, IL-1β and TNFα-mediated disease. IL-6-, IL-1β and / or TNFα-mediated diseases that can be treated with compounds comprising a structure having formula (I) include, but are not limited to, the diseases discussed in this application.
[0211] In some embodiments, the inflammatory disease, autoimmune disease, or both are selected from
[0212] acne vulgaris,
[0213] Agammaglobulinemia,
[0214] Allergic rhinitis,
[0215] Amyloidosis,
[0216] Allergic reactions,
[0217] Ankylosing spondylitis,
[0218] Anti-GBM / anti-TBM nephritis (anti-glomerular basement membrane antibody disease),
[0219] Antiphospholipid syndrome,
[0220] Autism,
[0221] Autoimmune hepatitis,
[0222] Autoimmune inner ear disease,
[0223] Atopic dermatitis,
[0224] asthma,
[0225] Castleman disease,
[0226] Celiac disease,
[0227] Chagas disease,
[0228] Chronic nonbacterial osteomyelitis,
[0229] Chronic prostatitis,
[0230] Chronic recurrent multifocal osteomyelitis,
[0231] Cogan syndrome,
[0232] Cold agglutinin disease,
[0233] CREST syndrome,
[0234] Crohn's disease,
[0235] Dermatomyositis,
[0236] Devic disease (neuromyelitis optica),
[0237] Discoid lupus,
[0238] Endometriosis,
[0239] Eosinophilic asthma,
[0240] Eosinophilic cardiomyopathy,
[0241] Eosinophilic colitis,
[0242] Eosinophilic cystitis,
[0243] Eosinophilic disorders,
[0244] Eosinophilic enteritis,
[0245] Eosinophilic esophagitis (EoE),
[0246] Eosinophilic fasciitis,
[0247] Eosinophilic gastritis,
[0248] Eosinophilic gastroenteritis,
[0249] Eosinophilic granuloma with polyangiitis,
[0250] Eosinophilic pneumonia,
[0251] Evans syndrome,
[0252] Fibromyalgia,
[0253] Food allergies,
[0254] Giant cell arteritis,
[0255] Giant cell myocarditis,
[0256] Glomerulonephritis,
[0257] Goodpasture syndrome (anti-GBM),
[0258] Granulomatosis with polyangiitis (Wegener's disease),
[0259] Graves' disease,
[0260] Guillain-Barre syndrome,
[0261] Hashimoto's thyroiditis,
[0262] Hemolytic anemia (some types),
[0263] Hemophagocytic lymphohistiocytosis,
[0264] Henoch-Schonlein purpura,
[0265] Hypereosinophilic syndrome,
[0266] Hypersensitivity reactions,
[0267] Hypogammaglobulinemia,
[0268] Hypoproliferative anemia,
[0269] IgA nephropathy,
[0270] Inclusion body myositis,
[0271] Interstitial cystitis,
[0272] Inflammatory bowel disease,
[0273] Juvenile arthritis,
[0274] Adolescents / Type 1 Diabetes,
[0275] Juvenile myositis,
[0276] Kawasaki syndrome,
[0277] lichen planus,
[0278] Lichen sclerosus,
[0279] Mastocytosis,
[0280] Meniere's disease,
[0281] Multiple sclerosis,
[0282] Myasthenia gravis,
[0283] Myopathy (certain types),
[0284] Microscopic polyangiitis,
[0285] Optic neuritis,
[0286] Paroxysmal nocturnal hemoglobinuria,
[0287] Pemphigus,
[0288] Perennial allergies,
[0289] Pernicious anemia,
[0290] Pelvic inflammatory disease,
[0291] Polyarteritis nodosa,
[0292] Polymyalgia rheumatica,
[0293] Polymyositis,
[0294] Primary biliary cirrhosis,
[0295] Primary sclerosing cholangitis,
[0296] psoriasis,
[0297] Psoriatic arthritis,
[0298] Reactive arthritis,
[0299] Reperfusion injury,
[0300] Rheumatic fever,
[0301] Rheumatoid arthritis,
[0302] Sarcoidosis,
[0303] scleroderma,
[0304] Seasonal allergies,
[0305] Selective IgA deficiency,
[0306] sickle cell disease,
[0307] Sjogren's syndrome,
[0308] Still's disease,
[0309] Systemic lupus erythematosus (SLE),
[0310] Systemic juvenile idiopathic arthritis,
[0311] Systemic sclerosis,
[0312] Takayasu arthritis,
[0313] Temporal arteritis / giant cell arteritis,
[0314] Transplant rejection,
[0315] Transverse myelitis,
[0316] ulcerative colitis,
[0317] Uveitis,
[0318] Vasculitis,
[0319] Vitiligo,
[0320] Viral myocarditis, and
[0321] Wegener's granulomatosis (granulomatosis with polyangiitis (GPA)).
[0322] In certain embodiments, the composition is administered orally. In other embodiments, the composition is administered by direct injection, topically and / or intravenously.
[0323] In some embodiments, the subject is selected from primates, humans, equines, horses, cattle, cows, pigs, sheep, rodents, rats, pets, dogs and guinea pigs. In certain preferred embodiments, the subject is a human. In other embodiments, the subject is a rodent. In other embodiments, the subject is selected from primates, equines, horses, cattle, cows, sheep, rats, pets, dogs and guinea pigs. In some embodiments, the subject is a female animal. In other embodiments, the subject is a male animal. In some embodiments, the subject is an infant, a child or an adult. In certain embodiments, the subject has elevated levels of IL-6, IL-1β and TNFα.
[0324] In some embodiments, the methods reduce mucus production in a subject.
[0325] In some embodiments, the method is a method for reducing the proliferation or activation of eosinophils in a subject. In some embodiments, the method is a method for reducing the proliferation or activation of lymphocytes in a subject. In some embodiments, the method is a method for reducing the proliferation or activation of macrophages in a thin subject. In some embodiments, the method is a method for reducing the proliferation or activation of T cells in a subject. In some embodiments, the method is a method for reducing the proliferation or activation of B cells in a subject. In some embodiments, the method is a method for reducing the proliferation or activation of neutrophils in a subject. In some embodiments, the method is a method for reducing the proliferation or activation of basophils in a subject. In some embodiments, the method is a method for reducing the proliferation or activation of a combination of macrophages, T cells, B cells, neutrophils, eosinophils, basophils, or lymphocytes in a subject.
[0326] On the other hand, provided herein is the use of a compound having a structure of formula (I) in the preparation of a medicament for treating autoimmune diseases and / or inflammatory diseases, such as IL-6, IL-1β and / or TNFα-mediated diseases. In some embodiments of this use, the compound is compound 1. In some embodiments of this use, the compound is compound 10.
[0327] Elevated levels of IL-6, IL-1β and / or TNFα have been found in patients with different diseases and studies have demonstrated that IL-6, IL-1β and / or TNFα contribute to the pathogenesis of these diseases.
[0328] These IL-6-, IL-1β and / or TNFα-mediated diseases may include diseases affecting the cardiac system, such as giant cell myocarditis, amyloidosis, viral myocarditis and / or rheumatic fever.
[0329] These IL-6-, IL-1 β and / or TNFα-mediated diseases may include diseases affecting the auditory system, such as autoimmune inner ear disease and / or Meniere's disease.
[0330] These IL-6-, IL-1β and / or TNFα-mediated diseases may include diseases affecting the endocrine system, such as Graves' disease, Hashimoto's thyroiditis, juvenile / type 1 diabetes, and / or amyloidosis.
[0331] These IL-6-, IL-1 β and / or TNFα-mediated diseases may include diseases affecting the gastrointestinal system, such as Crohn's disease, eosinophilic esophagitis, inflammatory bowel disease, ulcerative colitis and / or celiac disease.
[0332] These IL-6-, IL-1β and / or TNFα-mediated diseases can include diseases affecting the hematological system, such as cold agglutinin disease, Evan's syndrome, hemolytic anemia, hypoproliferative anemia, pernicious anemia, antiphospholipid syndrome, agammaglobulinemia, hypogammaglobulinemia, hemophagocytic lymphohistiocytosis, paroxysmal nocturnal hemoglobinuria, sickle cell disease and / or reperfusion injury.
[0333] These IL-6-, IL-1β and / or TNFα-mediated diseases may include diseases affecting the liver system, such as primary sclerosing cholangitis, primary biliary cirrhosis and / or autoimmune hepatitis.
[0334] These IL-6-, IL-1β and / or TNFα-mediated diseases can include diseases affecting the immune system, such as allergic rhinitis, anaphylaxis, hypersensitivity reactions, lupus (SLE), mastocytosis, perennial allergies, seasonal allergies, Sjögren's syndrome, transplant rejection, food allergies, celiac disease, agammaglobulinemia, hypogammaglobulinemia, scleroderma, selective IgA deficiency, and / or microscopic polyangiitis.
[0335] These IL-6-, IL-1β and / or TNFα-mediated diseases may include diseases affecting the systemic response to infection, such as Chagas disease.
[0336] These IL-6-, IL-1β and / or TNFα-mediated diseases may include diseases affecting the lymphatic system, such as Castleman's disease and / or sarcoidosis.
[0337] These IL-6-, IL-1β and / or TNFα-mediated diseases can include diseases affecting the muscular system, such as dermatomyositis, inclusion body myositis, certain types of myopathy, polymyositis, viral myocarditis, Guillain-Barre syndrome, fibromyalgia, myasthenia gravis, scleroderma, and / or juvenile myositis.
[0338] These IL-6-, IL-1β and / or TNFα-mediated diseases may include diseases affecting the nervous system, such as Guillain-Barre syndrome, Devic's disease (neuromyelitis optica), multiple sclerosis, transverse myelitis, optic neuritis and / or myasthenia gravis.
[0339] These IL-6-, IL-1 β and / or TNFα-mediated diseases may include diseases affecting the visual system, such as uveitis and / or optic neuritis.
[0340] These IL-6-, IL-1β and / or TNFα-mediated diseases may include diseases affecting the psychiatric system, such as autism.
[0341] These IL-6-, IL-1 β and / or TNFα-mediated diseases may include diseases affecting the renal system, such as glomerulonephritis and / or IgA nephropathy.
[0342] These IL-6-, IL-1 β and / or TNFα-mediated diseases may include diseases affecting the respiratory system, such as asthma and / or sarcoidosis.
[0343] These IL-6-, IL-1β and / or TNFα-mediated diseases may include diseases affecting the rheumatic system, such as ankylosing spondylitis, anti-GBM / anti-TBM nephritis, chronic relapsing multifocal osteomyelitis, Cogan's syndrome, Goodpasture's syndrome (anti-GBM), juvenile arthritis, polymyalgia rheumatica, rheumatoid arthritis, CREST syndrome, eosinophilic fasciitis, psoriatic arthritis, antiphospholipid syndrome, amyloidosis and / or rheumatic fever.
[0344] These IL-6-, IL-1β and / or TNFα-mediated diseases can include diseases affecting the skin and connective tissue system, such as CREST syndrome, eosinophilic fasciitis, acne vulgaris, atopic dermatitis, discoid lupus, Henoch-Schwann purpura, lichen planus, lichen sclerosus, pemphigus, psoriasis, vitiligo, juvenile myositis, sarcoidosis, psoriatic arthritis, scleroderma and / or rheumatic fever.
[0345] These IL-6-, IL-1 β and / or TNFα-mediated diseases may include diseases affecting the urinary system, such as chronic prostatitis and / or interstitial cystitis.
[0346] These IL-6-, IL-1 β and / or TNFα-mediated diseases may include diseases affecting the reproductive system, such as endometriosis and / or pelvic inflammatory disease.
[0347] These IL-6-, IL-1β, and / or TNFα-mediated diseases can include diseases affecting the vasculature, such as giant cell arteritis, granulomatosis with polyangiitis (Wegener's disease), Kawasaki syndrome, polyarteritis nodosa, temporal arteritis / giant cell arteritis, vasculitis, scleroderma, microscopic polyangiitis, and / or reperfusion injury.
[0348] In some embodiments, the disease or disorder is an eosinophilic disorder selected from eosinophilic asthma, eosinophilic cardiomyopathy, eosinophilic colitis, eosinophilic cystitis, eosinophilic enteritis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic granuloma with polyangiitis, eosinophilic pneumonia, and hypereosinophilic syndrome.
[0349] In some embodiments, the disease or condition is selected from EoE, asthma, inflammatory bowel disease, rheumatoid arthritis, or multiple sclerosis. In certain embodiments, the disease or condition is asthma, inflammatory bowel disease, or type 1 diabetes. In certain preferred embodiments, the disease or condition is EoE. EoE is a chronic immune and antigen-mediated disease characterized by infiltration of eosinophils into esophageal tissue, leading to dysphagia, food impaction, regurgitation or vomiting, and decreased appetite. It is defined by symptoms and the finding of large numbers of eosinophils in esophageal tissue by endoscopic biopsy (eosinophils are not normally found in the esophagus). Currently, there are no drugs approved for the treatment of EoE in the United States. However, there are trial and error approaches to different categories of treatment, including food elimination, off-label use of steroids, and surgical intervention. Between 40-50% of patients do not respond to first-line treatment.
[0350] In some embodiments, provided herein is a method for reducing IL-6-, IL-1β and / or TNFα production from a cell, the method comprising contacting the cell with a composition comprising a compound having a structure of formula (I) or (II). In some embodiments of the method, the compound is compound 1. In some embodiments of the method, the compound is compound 10.
[0351] In some embodiments of any of the methods disclosed herein, the compound of formula (I) is selected from
[0352]
[0353]
[0354]
[0355]
[0356] In some embodiments of any of the methods disclosed herein, the compound of formula (I) is selected from
[0357]
[0358]
[0359] In some embodiments of any of the methods, the compound of formula (II) is selected from
[0360]
[0361] Such methods can be performed in vivo or in vitro.
[0362] In some embodiments, administration of a compound having the structure of Formula (I) modulates drug metabolism and pharmacokinetics compared to other ascaroside compounds or derivatives, such as ascr#7. In some embodiments, administration of a compound having the structure of Formula (I) or (II) modulates one or more of: IL-6 production from cells, IL-1β production from cells, TNFα production from cells, CCL26 production from cells, stability in hepatocytes, stability in plasma, bidirectional permeability in various cells or systems (e.g., intestinal barrier), plasma protein binding, CYP inhibition, metabolites (e.g., produced in the liver), and / or compound absorption (e.g., based on lipophilicity).
[0363] Pharmaceutical composition
[0364] In another aspect, provided herein is a pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a compound having a structure of formula (I):
[0365]
[0366] in
[0367] Ring D is selected from
[0368] represents the point of attachment of ring D to the oxygen atom;
[0369] X is -C(R 5 )2-C(R 5 )2- or E or Z-CH=CH-;
[0370] Y is O or NR 6 ;
[0371] R is H or CH3;
[0372] R 1 is H or CH3;
[0373] Or, R and R 1 Together with the carbon atoms to which they are bonded, they form a 3- or 4-membered carbocyclic ring;
[0374] R 2 is H or CH3;
[0375] R 3 is H or CH3;
[0376] R 4 is CH3, CH2CH3, a linear or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, a C1-C6 alkyl group substituted with an aryl group, or a C1-C6 alkyl group substituted with a heterocyclic group;
[0377] R 5 Each occurrence is independently H or OH,
[0378] or two R 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring; and
[0379] R 6 is H or C1-C6 alkyl,
[0380] Or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bonded, they form a 5- or 6-membered heterocyclic ring.
[0381] In some embodiments of the pharmaceutical formulation, X is -C(R 5 )2-C(R 5 )2-. In some embodiments, X is E or Z-CH=CH-. In some embodiments, X is -C(H)2-C(H)2-. In some embodiments, X is -C(H)(OH)-C(H)2-.
[0382] In some embodiments, XC(R 5 )2-C(R 5 2. Two Rs 5 Together with the carbon atoms to which they are bonded, they form a 3-membered carbocyclic ring. In some embodiments, X is In some embodiments, X is In some embodiments, X is In some embodiments, X is
[0383] In some embodiments of the pharmaceutical formulation, Y is NR 6 In some embodiments, Y is NR 6 , where R 6 is H. In some embodiments, Y is NR 6 , where R 6 is C1-C6 alkyl. In some embodiments, Y is NR 6 , where R 6 In some embodiments, Y is NR 6 , where R 6 In some embodiments, Y is NR 6 , where R 4 and NR 6 Together with the carbon atoms to which they are bound, they form a 5- or 6-membered heterocyclic ring.
[0384] In some embodiments of the pharmaceutical formulation, R and R 1 Each is CH3. In some embodiments, R and R 1 Each is CH3. In some embodiments, R is CH3; and R 1 is H. In some embodiments, R and R 1 Together with the carbon atom to which they are bonded, they form a cyclopropyl group. 1 Together with the carbon atom to which they are bonded they form a cyclobutyl group.
[0385] In some embodiments of the pharmaceutical formulation, R 2 H; R 3 is H or CH3; and R 4 is CH3, CH2CH3, a straight or branched C3-C6 alkyl group, a C5-C7 cycloalkyl group, a 6-membered aryl or heteroaryl group, an aryl-substituted C1-C6 alkyl group or a heterocyclic-substituted C1-C6 alkyl group, or, when Y is NR 6 When R 4 and NR 6 Together with the carbon atoms to which they are bound, they form a 5-membered or 6-membered heterocyclic ring. 2 , R 3 and R 4 Each is CH3. In some embodiments, R 2 H; R 3 is CH3; and R 4 is CH3. In some embodiments, R 2 H; R 3 is H; and R 4 is CH2CH3. In some embodiments, R 2 H; R 3 is H; and R 4 is CH(CH2CH3)2. In some embodiments, R 2 H; R 3 is H; and R 4 is CH(CH2CH3)2. In some embodiments, R 2 H; R 3 is H; and R 4 In some embodiments, R 2 H; R 3 is H; and R 4 In some embodiments, R 2 H; R 3 is H; and R 4 It is pyridyl.
[0386] In some embodiments of the pharmaceutical formulation, the compound of formula (I) is selected from
[0387] In some embodiments of the pharmaceutical formulation, the compound of formula (I) is selected from
[0388]
[0389]
[0390]
[0391]
[0392] In some embodiments of the pharmaceutical formulation, the compound of formula (I) is selected from
[0393]
[0394] In another aspect, provided herein is a pharmaceutical composition comprising a pharmaceutically acceptable carrier; and a compound having a structure of formula (II):
[0395]
[0396] in
[0397] Ring D is selected from
[0398] represents the point of attachment of ring D to the oxygen atom; and
[0399] A double bond or a single bond.
[0400] In some embodiments of the pharmaceutical formulation, the compound of formula (II) is a compound having the following structural formula:
[0401]
[0402] In some embodiments of the pharmaceutical formulation, the compound of formula (II) is a compound having the following structural formula:
[0403]
[0404] In some embodiments of the pharmaceutical formulation, the compound of formula (II) is selected from
[0405]
[0406] The compounds, compositions and methods described in this application can be used to treat subjects in need thereof. In certain embodiments, the subject is a mammal, such as a human or non-human mammal. When applied to an animal, such as a human, the composition or compound is preferably administered as a pharmaceutical composition, comprising, for example, a compound of the present invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions, such as water or physiologically buffered saline or other solvents or media, such as glycols, glycerol, oils such as olive oil or injectable organic esters. In a preferred embodiment, when such pharmaceutical compositions are used for human administration, particularly for invasive administration routes (i.e., bypassing routes of transport or diffusion through epithelial barriers, such as injection or implantation), the aqueous solution is pyrogen-free or substantially pyrogen-free. Excipients can be selected, for example, to delay the release of an active agent or selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form, such as tablets, capsules (including sprinkle capsules and gelatin capsules), granules, lyophilized agents for reconstitution, powders, solutions, syrups, suppositories, injections, etc. The composition may also be in the form of a transdermal delivery system, such as a skin patch. The composition may also be in the form of a solution suitable for topical administration, such as eye drops.
[0407] The pharmaceutical composition (formulation, formulation) can be administered to a subject by any of a variety of routes of administration, including, for example, orally (e.g., as a drench, tablet, capsule (including powder capsules and gelatin capsules) in an aqueous or non-aqueous solution or suspension, bolus, powder, granules, paste applied to the tongue); absorbed through the oral mucosa (e.g., sublingually); through the anus; through the rectum or through the vagina (e.g., as a vaginal suppository, cream or foam); through parenteral (including intramuscular, intravenous, subcutaneous or intrathecal, as, for example, a sterile solution or suspension); through the nose; through the peritoneum; through the subcutaneous; transdermally (e.g., as a patch applied to the skin); and topically (e.g., as a cream, ointment or spray applied to the skin, or as eye drops). The compound can also be formulated for inhalation. In certain embodiments, the compound can be simply dissolved or suspended in sterile water. Details of suitable routes of administration and compositions suitable for such routes can be found, for example, in the following patents: U.S. Patent Nos. 6,110,973, 5,731,000, 5,541,231, 5,427,798, 5,358,970, and 4,172,896, and patents cited therein.
[0408] It will be appreciated by those skilled in the art that the method of administering the formulation or composition of the present disclosure depends on a variety of factors, such as factors such as age, weight, and physical condition of the subject being treated and the disease or condition being treated. Therefore, those skilled in the art can select the best method of administration for the subject on a case-by-case basis.
[0409] A pharmaceutically acceptable carrier may comprise a physiologically acceptable substance, which, for example, acts to stabilize a compound such as the compounds of the invention, increase its solubility, or increase its absorption. Such physiologically acceptable agents include, for example, carbohydrates such as glucose, sucrose, or dextran; antioxidants such as ascorbic acid or glutathione; chelating agents; low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier comprising a physiologically acceptable substance depends, for example, on the route of administration of the composition. The formulation or pharmaceutical composition may be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical composition (formulation) may also be a liposome or other polymer matrix, into which, for example, the compounds of the invention may be incorporated. Liposomes, for example, comprising phospholipids or other lipids, are non-toxic, physiologically acceptable and metabolizable carriers that can be prepared and administered relatively easily.
[0410] As used in this application, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0411] As used in this application, the phrase "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition, or medium, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Some examples of pharmaceutically acceptable materials include: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, etc. and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer solution; and (21) other non-toxic compatible substances used in pharmaceutical formulations.
[0412] These preparations can be conveniently presented in dosage unit form and can be prepared by any method well known in the pharmaceutical field. The amount of active ingredient that can be combined with a carrier material to produce a single dose form can be changed according to the subject being treated, the specific mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dose form is generally the amount that the compound produces a therapeutic effect. Usually, in 100%, this amount will be about 1% to about 99% of the active ingredient, preferably about 5% to about 70%, and most preferably about 10% to about 30%.
[0413] The method for preparing these preparations or compositions comprises the step of combining active compound, for example compound of the present invention with carrier and optionally one or more auxiliary components.Usually, the preparation is prepared by uniformly and intimately combining compound of the present invention with liquid carrier or solid fine powder carrier or both of them, and then shaping the product if necessary.
[0414] Formulations of the present invention suitable for oral administration may be in the form of capsules (including powder capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), lyophilisates, powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid or as pastilles (using an inert base, such as gelatin and glycerin or sucrose and acacia) and / or as a mouthwash, etc., each containing a predetermined amount of the compound of the present invention as the active ingredient. The composition or compound may also be administered as a bolus, syrup or paste.
[0415] To prepare solid dosage forms for oral administration (capsules (including powder capsules and gelatin capsules), tablets, pills, lozenges, powders, granules, etc.), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate and / or any of the following substances: (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or gum arabic; (3) humectants, such as Glycerol; (4) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; (5) dissolution retardants, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glyceryl monostearate; (8) absorbents, such as kaolin and bentonite; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof; (10) compounding agents, such as modified and unmodified cyclodextrins; and (11) coloring agents. In the case of capsules (including powder capsules and gelatin capsules), tablets and pills, the pharmaceutical composition may also contain a buffer. Solid compositions of a similar type may also be used as fillers for soft and hard gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols and the like.
[0416] Tablets can be prepared by compression or molding optionally with one or more auxiliary ingredients. Compressed tablets can be prepared using a binder (e.g., gelatin or hydroxypropyl methylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), a surface active or dispersant. Molded tablets can be prepared by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine.
[0417] Tablets and other solid dosage forms of pharmaceutical compositions, such as lozenges, capsules (including powder capsules and gelatin capsules), pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other pharmaceutical coatings well known in the art. They may also be formulated to provide sustained or controlled release of the active ingredient therein, for example, using hydroxypropylmethylcellulose in different proportions to provide the desired release characteristics, other polymer matrices, liposomes and / or microspheres. They may be sterilized, for example, by filtering through a filter that retains bacteria immediately before use, or by incorporating a sterilizing agent in the form of a sterile solid composition soluble in sterile water, or some other sterile injectable medium. These compositions may also optionally contain an opacifier, and may have a composition that releases the active ingredient only or preferentially in a certain part of the gastrointestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. If appropriate, the active ingredient may also be in microencapsulated form, wherein one or more of the above-mentioned excipients are used.
[0418] Liquid dosage forms that can be used for oral administration include pharmaceutically acceptable emulsions, lyophilisates for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage form may also contain an inert diluent commonly used in the art, for example, water or other solvents, cyclodextrins and their derivatives, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (particularly cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan and mixtures thereof.
[0419] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0420] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0421] Formulations of pharmaceutical compositions for oral administration may be presented as a mouthwash or oral spray or oral ointment.
[0422] Alternatively, or in addition, the composition can be formulated to be delivered via a catheter, stent, wire or other intraluminal device. Delivery via such devices is particularly useful for delivery to the bladder, urethra, ureter, rectum or intestine.
[0423] Formulations suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or sprays containing such carriers as are known in the art to be appropriate.
[0424] Dosage forms for topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier and any preservatives, buffers or propellants that may be required.
[0425] Ointments, pastes, creams and gels may contain, in addition to the active compounds, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
[0426] Powders and sprays may contain, in addition to the active compounds, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays may also contain customary propellants, such as chlorofluorocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0427] Transdermal patches also have the additional advantage of providing controlled delivery of the compounds of this invention to health. This dosage form can be prepared by dissolving or dispersing the active compound in a suitable medium. Absorption enhancers can also be used to increase the flow of the compound through the skin. The rate of this flow can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or a gel.
[0428] It is also contemplated that ophthalmic preparations, eye ointments, powders, solutions, etc. are within the scope of the present invention. Example ophthalmic preparations are described in U.S. Publication Nos. 2005 / 0080056, 2005 / 0059744, 2005 / 0031697, and 2005 / 004074 and U.S. Patent No. 6,583,124, the contents of which are incorporated herein by reference. If desired, liquid ophthalmic preparations have properties similar to tears, aqueous humor, or vitreous humor or are compatible with such fluids. Preferred routes of administration are topical (e.g., topical, such as eye drops, or by implant application).
[0429] As used in this application, the phrases "parenteral administration" and "administered parenterally" mean modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
[0430] Pharmaceutical compositions suitable for parenteral administration comprise one or more active compounds in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into a sterile injectable solution just before use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.
[0431] Suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil and injectable organic esters, such as ethyl oleate. Suitable fluidity can be maintained, for example, by using coating materials such as lecithin, by maintaining the desired particle size in the case of dispersions, and by using surfactants.
[0432] These compositions can also include adjuvants, such as preservatives, wetting agents, emulsifiers and dispersants. The effects of microorganisms can be prevented by adding various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. It is also desirable to include isotonic agents in the composition, such as sugar, sodium chloride, etc. In addition, the extended absorption of injectable drug forms can be achieved by including agents that delay absorption (such as aluminum monostearate and gelatin).
[0433] In some cases, in order to prolong the effect of the drug, it is desirable to slow down the absorption of the drug from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystals or amorphous materials with poor water solubility. The absorption rate of the drug depends on its dissolution rate, which in turn may depend on the crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is achieved by dissolving or suspending the drug in an oily medium.
[0434] Injectable reservoirs are prepared by forming a microencapsulation matrix of the subject compound in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of the drug to the polymer and the specific polymer properties used, the drug release rate can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Reservoir-type injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
[0435] For use in the methods of the invention, the active compound may be administered per se or in the form of a pharmaceutical composition comprising, for example, 0.1-99.5% (more preferably 0.5-90%) of the active ingredient in combination with a pharmaceutically acceptable carrier.
[0436] The introduction method can also be provided by rechargeable or biodegradable devices. In recent years, various slow-release polymer devices have been developed and tested in vivo for controlled delivery of drugs, including protein biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including biodegradable and non-degradable polymers can be used to form implants for sustained release of compounds at specific target sites.
[0437] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
[0438] The selected dosage level will depend upon a variety of factors including the activity of the specific compound or combination of compounds employed or their esters, salts or amides, the route of administration, the time of administration, the rate of excretion of the specific compound employed, the duration of the treatment, other drugs, compounds and / or compounds and / or materials used in combination with the specific compound employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated and other factors well known in the medical art.
[0439] A physician or veterinarian with ordinary skills in the art can easily determine and prescribe the therapeutically effective amount of the desired pharmaceutical composition. For example, a clinician or veterinarian can start a dose of a pharmaceutical composition or compound below the desired level to achieve the desired therapeutic effect, and gradually increase the dose until the desired effect is achieved. The so-called "therapeutically effective amount" refers to a concentration of a compound sufficient to cause the desired therapeutic effect. It is generally understood that the effective amount of a compound will vary depending on the subject's weight, sex, age and medical history. Other factors affecting the effective amount may include, but are not limited to, the severity of the subject's condition, the disease being treated, the stability of the compound, and the type of another therapeutic agent to be administered with the compound of the present invention if desired. A larger total dose can be provided by multiple administrations of the active agent. Methods for determining efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison's Principles of Internal Medicine 13th Edition, 1814-1882, incorporated herein by reference).
[0440] In general, a suitable daily dose of an active compound used in the compositions and methods of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend on the factors described above.
[0441] If desired, the effective daily dose of the active compound may be administered as one, two, three, four, five, six or more sub-doses, which are administered separately at appropriate intervals throughout the day, optionally, in unit dosage form. In certain embodiments of the invention, the active compound may be administered twice or three times daily. In a preferred embodiment, the active compound is administered once daily.
[0442] The subject receiving such treatment is generally any animal in need thereof, including primates, particularly humans, and other mammals, such as horses, cattle, pigs, and sheep; as well as poultry and pets.
[0443] In certain embodiments, the compounds of the present invention can be used alone or in combination with another type of therapeutic agent. As used in the present application, the phrase "combined administration" refers to any form of administration of two or more different therapeutic compounds, so that the previously administered therapeutic compound is still effective in vivo while the second compound is administered (for example, two compounds are effective in the subject at the same time, which can include the synergistic effect of the two compounds). For example, different therapeutic compounds can be used in the same preparation at the same time or in sequence or in a separate preparation. In certain embodiments, different therapeutic compounds can be used within 1 hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours or within a week. Therefore, the subject receiving this treatment can benefit from the combined effect of different therapeutic compounds.
[0444] In some embodiments, the different therapeutic compound is a steroid. In some embodiments, the different therapeutic compound is a steroid selected from the group consisting of hydrocortisones, chlorpheniramines, betamethasones, esters, halogenated steroids, and unstable prodrug esters. In some embodiments, the steroid is selected from the group consisting of allclomethasone dipropionate, aldosterone, amcinonide, beclomethasone, betamethasone, betamethasone dipropionate, betamethasone valerate, budesonide, ciclesonide, clobetasol propionate, cloflumethasone butyrate, corticosterone, cortisol, cortisone, cortisone acetate, desonide, dexamethasone (DEX), fluocinolone, fluocinolone acetate, fluocortolone, flumethadone acetate, halcitonide, halometasone, hydrocortisone, hydrocortisone acepromazine, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone valerate, methylprednisolone, mometasone, mometasone furoate, prednicarb, prednisolone, prednisone, triamcinolone and tixocortolone pivalate. In some embodiments, the steroid is DEX. In some embodiments, the compound of formula (I) is administered in combination with a steroid. In some embodiments, the compound of formula (I) is administered in combination with DEX.
[0445] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coatings, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0446] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.; and (3) metal chelators, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc. Example
[0447] The following examples are provided to better illustrate the claimed invention, and the examples should not be construed as limiting the scope of the invention. To the extent that specific materials are mentioned, this is for illustrative purposes only and is not intended to limit the invention. Those skilled in the art may develop equivalent means or reactants without exercising creative ability and without departing from the scope of the invention.
[0448] Example 1
[0449] Synthesis of compound 1:
[0450] This compound was synthesized according to the following scheme.
[0451]
[0452] Synthesis of compound 10:
[0453] This compound was synthesized according to the following scheme.
[0454]
[0455] Example 2
[0456] I. General Synthesis
[0457] The compounds of the present invention were prepared using the methods exemplified in the general synthetic schemes and the experimental procedures described in detail below. These general synthetic schemes and experimental procedures are provided for illustrative purposes only and are not intended to be limiting. The starting materials used to prepare the compounds of the present invention are either commercially available or can be prepared using conventional methods known in the art. If available, the names of the compounds were generated using ChemAxon's Instant JChem v6.1 and IUPAC Naming Plugin for Desktop or ChemDraw Professional 16.0.1.4 (61).
[0458] General methods for the synthesis of ascaroside pheromones and related compounds have been previously described in the literature, such as Jeong P.Y. et al. Chemical structure and biological activity of the Caenorhabditis elegans dauer-inducing pheromone. Nature 2005, 433(7025), 541-545; Martin, R. et al. Improved Synthesis of an Ascaroside Pheromone Controlling Dauer Larva Development in Caenorhabditis elegans. Synthesis 2009, 20, 3488–3492; and Zhang, YK et al. Improved Synthesis for Modular Ascarosides Uncovers Biological Activity. Org. Lett. 2017, 19, 2837-2840, each of which is incorporated into the present application by reference.
[0459] The protected carbohydrate (I) containing a free anomeric hydroxyl group is activated by preparing O-glycosyl trichloroacetimidate (II), which is prepared using trichloroacetonitrile (Cl3CCN) under basic conditions (e.g., DBU, DIPEA, etc.). The scheme illustrates the reaction of O-glycosyl trichloroacetimidate (II) with a Lewis acid such as BF3·OEt2 or TMSOTf in the presence of an alcohol to give the O-glycosylated product (III).
[0460] Scheme 1. General synthesis of O-glycosylated products (III) from O-glycosyl trichloroacetimidate (II).
[0461]
[0462] Scheme 2 illustrates the reaction of an O-glycosylated terminal olefin (IV) with a suitable α,β-unsaturated ester or amide using Grubb olefin transfer catalysis (e.g., dichloro[1,3-bis(2,6-isopropylphenyl)-2-imidazolidinylidene](benzylidene)(tricyclohexylphosphine)ruthenium(II), (1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(phenylmethylene)(tricyclohexylphosphine)ruthenium, benzylidene-bis(tricyclohexylphosphine)dichlororuthenium, bis(tricyclohexylphosphine)benzylideneruthenium(IV)dichloride, etc.) to afford an O-glycosylated (E)-isomer α,β-unsaturated ester or amide (V).
[0463] Scheme 2. General synthesis of O-glycosylated (E)-isomer α,β-unsaturated esters or amides (V) from terminal olefins (IV) of O-glycosylated compounds
[0464]
[0465] Scheme 3 illustrates the oxidation of O-glycosylated terminal olefins (IV) using Lemieux oxidation (OsO4 and NaIO4) or ozonolysis (O3) conditions to give O-glycosylated aldehydes (VI).
[0466] Scheme 3. General synthesis of O-glycosylated aldehydes (VI) from O-glycosylated terminal olefins (IV).
[0467]
[0468] Scheme 4 illustrates the Still-Gennari olefination of O-glycosylated aldehydes (IV) to afford O-glycosylated (Z)-isomer α,β-unsaturated esters or amides (VII). (Z)-stereospecific Still-Gennari olefination conditions use a bistrifluoroethyl phosphonate (e.g., (methoxycarbonylmethyl)phosphonic acid bis(2,2,2-trifluoroethyl) ester), ((ethoxycarbonylmethyl)phosphonic acid bis(2,2,2-trifluoroethyl) ester), etc.), a strong base such as KHMDS, and a cation scavenger such as 18-crown-6.
[0469] Scheme 4. General synthesis of O-glycosylated (Z)-isomer α,β-unsaturated esters or amides (VII) from O-glycosylated aldehydes (VI).
[0470]
[0471] Scheme 5 illustrates the coupling of O-glycosylated carboxylic acids (VIII) with alcohols to form O-glycosylated esters (IX). O-glycosylated carboxylic acids (VIII) are prepared by base or acid hydrolysis of simple esters (e.g., methyl, ethyl, tert-butyl) derived from the Grubb olefin transfer method (Scheme 2). Several esterification methods are possible from VIII to IX ketocarbamate IV: 1) IIIV with alcohols (HO-C(R 2 )(R 3 )(R 4 1) using a coupling reagent (e.g. N,N'-dicyclohexylcarbodiimide (DCC), EDC, HBTU, HATU, TBTU, PyBOP, etc.) under alkaline conditions (e.g. triethylamine, diisopropylethylamine, pyridine, N,N-4-dimethylaminopyridine, etc.); 2) using an activated alkane (XC(R 2 )(R 3 )(R 4)), wherein X = Otf, Ots, Oms, I, Br and Cl) under basic conditions (e.g., NaOH, NaH, NaCO3, K2CO3, Cs2CO3, NaHCO3, etc.); and 3) alkylation of IIIV with an alcohol (HO-C(R 2 )(R 3 )(R 4 )), IIIV is esterified using Mitsunobu conditions (eg diethyl azodicarboxylate and triphenylphosphine or similar reagents).
[0472] Scheme 5. General synthesis of O-glycosylated esters (IX) from O-glycosylated carboxylic acids (VIII).
[0473]
[0474] Scheme 6 illustrates the coupling of O-glycosylated carboxylic acids (VIII) with amines to form O-glycosylated amides (X). Under basic conditions (e.g., triethylamine, diisopropylethylamine, pyridine, N,N-4-dimethylaminopyridine) in the presence of amines (N(C-(R 2 )(R 3 )(R 4 ))R 6 ) and a coupling reagent (e.g., N,N'-dicyclohexylcarbodiimide (DCC), EDC, HBTU, HATU, TBTU, PyBOP, etc.).
[0475] Scheme 6. General synthesis of O-glycosylated amides (X) from O-glycosylated carboxylic acids (VIII).
[0476]
[0477] Scheme 7 illustrates the cyclopropanation of O-glycosylated terminal olefins (IV) under standard diazocyclopropanation conditions using a tetracarboxylic acid rhodium catalyst (e.g., rhodium(II) acetate dimer, rhodium(II) trifluoroacetate dimer, tetrakis[N-phthaloyl-(S)-tert-leucine]dirhodium, tetrakis[methyl 2-pyrrolidone-5(S)-carboxylate]dirhodium(II), etc.) to form O-glycosylated trans-cyclopropyl esters or amides (XI).
[0478] Scheme 7. General synthesis of O-glycosylated trans-cyclopropyl esters or amides (XI) from O-glycosylated terminal olefins (IV).
[0479]
[0480] Scheme 8 illustrates the cyclopropanation of the O-glycosylated (Z)-isomer α,β-unsaturated ester or amide (VII) to form the O-glycosylated cis-cyclopropyl ester or amide (XII). Several methods are possible, using Corey-Chaykovsky cyclopropanation conditions (e.g. dimethyloxosulfoniummethyl ylides, which are prepared using trimethyloxosulfonium iodide in DMSO and sodium hydride) or Simmons–Smith conditions (e.g. iodomethylzinc iodide, which is prepared using diiodomethane and a zinc-copper couple).
[0481] Scheme 8. General synthesis of O-glycosylated cis-cyclopropyl esters or amides (XII) from O-glycosylated (Z)-isomer α,β-unsaturated esters or amides (VII) from O-glycosylated aldehydes (VI).
[0482]
[0483] II. Experimental Section
[0484] General information:
[0485] All chemical reagents were purchased commercially and used without further purification unless otherwise stated. Column chromatography was performed using silica gel 60 (230-400 mesh) and analytical TLC was performed using silica gel coated plates. TLC plates were stained with cerium ammonium molybdate (CAM), p-anisaldehyde (Anis), potassium permanganate (KMnO4) or ninhydrin stain. The results were recorded using an automated Varian Inova 500 MHz (MestReNova software: version 14.1.2-25024) or Bruker 400 MHz using conventional deuterated solvents such as deuterium oxide, chloroform-d or methanol-d4. 1 H NMR spectra. LCMS was performed using a Shimadzu LC-20AD pump and LCMS-2020 single quadrupole liquid chromatograph mass spectrometer. Mass spectrometry was performed using an Agilent 1290 UHPLC system equipped with a G4212 DAD and a G6140 MS detector (ESI: positive or negative ion mode). 18The samples were analyzed at a flow rate of 0.5-1.0 mL / min using a column (2.1 mm x 50 mm) with gradient elution (mobile phase A: 0.05% TFA in water; mobile phase B: acetonitrile containing 0.1% AcOH or 0.025% TFA). Gas chromatography analysis was performed using an Agilent GC equipped with a flame ionization detector, using an Agilent J&W CYCLOSIL-B (30 m x 250 μm x 0.25 μm) column (conditions: inlet temperature: 200°C; run time: 60 min; flow rate: 1 mL / min; carrier gas: helium; detector temperature: 240°C).
[0486] Preparation of benzoic acid (2S, 3R, 5R, 6S)-5-(benzoyloxy)-2-methyl-6-[(trichloroacetimidyl)oxy]oxan-3-yl ester (C-01):
[0487]
[0488] Benzoic acid (2S, 3R, 5R)-5-(benzoyloxy)-6-hydroxy-2-methyloxan-3-yl ester (40.0 g, 112 mmol, 1.00 eq.) was dissolved in DCM (200 mL), and trichloroacetonitrile (81.0 g, 561 mmol, 56.2 mL, 5.00 eq.) was added to the reaction system. The mixture was degassed with nitrogen three times and cooled to 0°C. DBU (8.54 g, 56.1 mmol, 8.46 mL, 0.50 eq.) was added dropwise to the reaction system at 0°C and stirred at 0°C for 1.5 h. TLC showed that the reaction was complete (3:1 petroleum ether-ethyl acetate, SMR). f =0.45, R f (C-01) = 0.80). The obtained black liquid C-01 was used directly without further purification.
[0489] Preparation of (2S,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-6-methyl-2-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-pyran-3-yl benzoate (C-02):
[0490]
[0491] To stirring benzoic acid (2R, 3R, 5R, 6S) -5- ((tert-butyldiphenylsilyl) oxygen base) -2-hydroxy -6- methyltetrahydro -2H- pyrans -3- base ester (7.30g, 14.90mmol) in DCM (50mL) solution, add CCl CN (3.10mL, 29.80mmol) and DBU (0.210mL, 1.50mmol). The resulting mixture is stirred for 18h at room temperature in a nitrogen atmosphere. The reaction system is concentrated in vacuo, then purified by column chromatography (220g silica gel, 0% -30% acetone in hexane), C-02 (4.5g, 48% yield) is obtained, which is a white foam. 1 H NMR (500MHz, CDCl3) δ8.65 (s, 1H), 7.81–7.76 (m, 2H), 7.71–7.65 (m, 4H), 7.61 (ddt, J=8.8, 7. 4, 1.3Hz, 1H), 7.46–7.41(m, 2H), 7.40–7.37(m, 1H), 7.37–7.32(m, 3H), 7.32–7.29(m, 2H), 6. 14 (s, 1H), 5.16 (dt, J = 4.5, 2.1 Hz, 1H), 4.09-4.01 (m, 1H), 3.76 (ddd, J = 11.1, 9.3, 4.4 Hz, 1H), 2.12 (ddd, J = 14.1, 11.2, 3.0 Hz, 1H), 2.07-2.00 (m, 1H), 1.35 (d, J = 6.2 Hz, 3H), 1.08 (s, 9H). Mass analysis (ESI, +ve) = 634.2 [M+H].
[0492] Using the above protocols, Table 1 summarizes additional carbohydrate starting materials that were prepared from commercially available reagents after assembly of appropriate protecting groups.
[0493] Table 1. Trichloroethane imide acyl carbohydrates
[0494]
[0495]
[0496] Preparation of (2R)-hex-5-en-2-ol (I-01):
[0497]
[0498] (R)-(+)-propylene oxide (99.0 g, 1.70 mol, 119 mL, 1.00 eq.) was dissolved in THF (534 mL). To the reaction mixture was added copper (I) bromide (24.4 g, 170 mmol, 5.19 mL, 0.10 eq.) in solid form. The reaction system was cooled to -70°C in a nitrogen atmosphere, and allyl magnesium bromide (1 M, 2.22 L, 1.30 eq.) was added dropwise to the reaction system for 4 h. The reaction system was warmed to 15°C and stirred at 15°C for 4 h. TLC showed that the reaction was complete (5:1 petroleum ether-ethyl acetate, R f (I-01) = 0.39). The reaction was quenched with aqueous ammonium chloride (1.0 L) at 0°C and then extracted with MTBE (3 x 5.0 L). The layers were separated and the organic layer was washed with brine (2 x 2.0 L). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo at 30°C. The residue was purified by column chromatography (silica gel, 5:1 petroleum ether-ethyl acetate) to give I-01 (43.3 g, 25% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl3) δ 5.87-5.80 (m, 1H), 5.06-4.95 (m, 1H), 3.84-3.82 (m, 1H), 3.81-3.79 (m, 1H), 2.18-2.11 (m, 1H), 1.61-1.52 (m, 2H), 1.19 (d, J = 6.0 Hz, 3H). Chiral GC: 99.9% ee.
[0499] Preparation of benzoic acid (2S, 3R, 5R, 6R)-5-(benzoyloxy)-6-[(2R)-hex-5-en-2-yloxy]-2-methyloxan-3-yl ester (T-01):
[0500]
[0501] Add crude C-01 solution Molecular sieves, degas the reaction system with nitrogen three times. Compound I-01 (12.3 g, 123 mmol, 1.10 eq.) was added to the reaction system at 25°C, and the mixture was cooled to -20°C. TMSOTf (12.4 g, 55.9 mmol, 10.1 mL, 0.50 eq.) was added dropwise to the reaction system at -20°C. The mixture was stirred at -20°C for 1.5 h. TLC showed that the reaction was complete (3:1 petroleum ether-ethyl acetate, SMR). f (C-01) = 0.80, R f(T-01) = 0.88). Water (500 mL) was added to quench the reaction, and the mixture was extracted with DCM (3 x 300 mL). The layers were separated and the organic layer was washed with brine (2 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 2:1 petroleum ether-ethyl acetate) to give T-01 (29.0 g, 59% yield) as a yellow oil. 1 H NMR (400MHz, CDCl3) δ 8.14-8.05 (m, 4H), 7.59-7.27 (m, 6H), 5.94-5.86 (m, 1H), 5.17-4.98 (m, 5H), 4.17-4.13 (m, 1H), 3. 92-3.87 (m, 1H), 2.46-2.42 (m, 1H), 2.27-2.20 (m, 3H), 1.79-1.63 (m, 2H), 1.32 (d, J=4.2Hz, 3H), 1.23 (d, J=4.2Hz, 3H).
[0502] Preparation of (2R,3R,5R,6S)-2-[(2R)-hex-5-en-2-yloxy]-6-methyloxane-3,5-diol (T-02):
[0503]
[0504] Compound T-01 (23.0 g, 52.4 mmol, 1.00 eq.) was dissolved in THF (160 mL), and then water (230 mL) was added at 25°C. Solid LiOH·H2O (22.0 g, 524 mmol, 10.0 eq.) was added to the reaction mixture, and the reaction system was heated to 70°C. After stirring for 16 h, TLC showed that the reaction was complete (5:1 petroleum ether-ethyl acetate, SMR). f (T-01) = 0.24, R f (T-02) = 0.00). The mixture was concentrated in vacuo at 40 °C to remove THF. Water (400 mL) was added and the mixture was extracted with ethyl acetate (3 x 400 mL). The layers were separated and the organic layer was washed with brine (2 x 400 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to give T-02 (12 g, crude) as a colorless oil, which was used directly without further purification.
[0505] Preparation of tert-butyl({[(2S,3R,5R,6R)-5-[(tert-butyldimethylsilyl)oxy]-6-[(2R)-hex-5-en-2-yloxy]-2-methyloxan-3-yl]oxy})dimethylsilane (T-03):
[0506]
[0507] Compound T-02 (11.0 g, 47.7 mmol, 1.00 eq.) was dissolved in THF (70 mL), and silver nitrate (20.2 g, 119 mmol, 2.50 eq.) and imidazole (13.0 g, 191 mmol, 4.00 eq.) were added in solid form. The reaction system was cooled to 0 ° C in a nitrogen atmosphere. Tert-butyldimethylsilyl chloride (21.6 g, 143 mmol, 3.00 eq.) was added to the reaction system and stirred at 25 ° C for 16 h. TLC showed that the reaction was complete. Water (200 mL) was added and the mixture was extracted with ethyl acetate (3 x 150 mL). The layers were separated and the organic layer was washed with brine (2 x 100 mL). The combined organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 20:1-10:1 petroleum ether-ethyl acetate) to give T-03 (14.0 g, 64% yield) as a yellow oil.
[0508] Preparation of (3R,5R,6R)-2-methyl-6-(pent-4-en-1-yloxy)tetrahydro-2H-pyran-3,5-diyl dibenzoate (T-04):
[0509]
[0510] To a solution of (2R,3R,5R)-2-hydroxy-6-methyltetrahydro-2H-pyran-3,5-diyl dibenzoate (0.300 g, 0.842 mmol) in DCM (15 mL) was added 4-penten-1-ol (0.260 mL, 2.52 mmol) and Molecular sieves (0.100 g). The reaction mixture was cooled to 0 ° C, and then BF3·Et2O (0.420 mL, 3.37 mmol) was added dropwise via a syringe. The resulting mixture was warmed to room temperature, stirred for 4 h, and then quenched with triethylamine (2 mL). The solvent was concentrated in vacuo and the crude product was purified by column chromatography (24 g silica gel, 0%-30% acetone in hexane) to give T-04 (0.200 g, 56%) as a colorless oil. 1H NMR (500MHz, CDCl3) δ8.16–8.11(m, 2H), 8.08–8.03(m, 2H), 7.64–7.57(m, 2H), 7.52–7.45( m, 4H), 5.88 (ddt, J=16.9, 10.2, 6.6Hz, 1H), 5.26–5.17 (m, 2H), 5.14–5.00 (m, 2H), 4.85 (s, 1H), 4.10 (dd, J = 9.7, 6.2 Hz, 1H), 3.81 (dt, J = 9.7, 6.6 Hz, 1H), 3.55 (dt, J = 9.6, 6.4 Hz, 1H), 2.44 (dt, J = 13.4, 3.9 Hz, 1H), 2.28-2.20 (m, 3H), 1.84-1.75 (m, 2H), 1.32 (d, J = 6.2 Hz, 3H). Mass analysis (ESI, +ve) = 425.2 [M+H].
[0511] Preparation of (2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-2-(((R)-hex-5-en-2-yl)oxy)-6-methyltetrahydro-2H-pyran-3-yl benzoate (T-05):
[0512]
[0513] To a stirred solution of C-02 (0.570 g, 0.900 mmol) in DCM (5 mL) was added (2R)-(-)-hex-5-ene-2-ol (0.165 mL, 1.35 mmol). The resulting mixture was cooled to 0 ° C and subsequently treated with TMSOTf (0.080 mL, 0.450 mmol). The reaction mixture was warmed to room temperature and stirred for 2 h in a nitrogen atmosphere. The resulting mixture was distributed between water (5 mL) and DCM (10 mL). The organic layer was washed with saturated NaHCO3 aqueous solution (5 mL), brine (5 mL), dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (40 g silica gel, 0%-30% acetone in hexane) to give T-05 (0.420 g, 82% yield) as a light brown oil. 1H NMR (500MHz, CDCl3) δ7.77–7.73 (m, 2H), 7.72–7.66 (m, 4H), 7.58 (ddt, J=8.8, 7.2, 1.3Hz, 1H), 7.43–7.38 (m, 3H), 7.37–7.29 (m, 5H) , 5.91 (ddt, J=16.9, 10.2, 6.5Hz, 1H), 5.12 (dq, J=17.1, 1.7Hz, 1H), 5.07–5.02 (m, 1H), 4.90 (td, J=3.1, 1.4Hz, 1H), 4.78 (s, 1H), 3.9 6–3.89 (m, 1H), 3.87–3.79 (m, 1H), 3.68 (ddd, J=11.2, 9.2, 4.3 Hz, 1H), 2.31–2.16 (m, 2H), 2.06 (ddd, J=14.0, 11.3, 3.0 Hz, 1H), 1.93–1.86 (m, 1H), 1.76 (dddd, J=13.4, 9.3, 7.4, 5.9 Hz, 1H), 1.65–1.58 (m, 1H), 1.29 (d, J=6.2 Hz, 3H), 1.17 (d, J=6.1 Hz, 3H), 1.08 (s, 9H). Mass analysis (ESI, +ve) = 573.2 [M+H].
[0514] Using the above protocol, the following carbohydrate alkane starting materials were prepared from the compounds in Table 2 and terminal enols. Disubstituted enols were prepared from ketones (eg, acetone, cyclopropanone, cyclobutanone) by reaction with 3-butenylmagnesium bromide.
[0515] Table 2. Carbohydrate terminal olefins
[0516]
[0517]
[0518] Preparation of tert-butyl({[(2S,3R,5R,6R)-5-[(tert-butyldimethylsilyl)oxy]-2-methyl-6-{[(2R)-4-(oxiran-2-yl)butan-2-yl]oxy}oxan-3-yl]oxy})dimethylsilane (I-02):
[0519]
[0520] Compound T-03 (6.00 g, 13.0 mmol, 1.00 eq.) was dissolved in DCM (42 mL). m-CPBA (3.95 g, 18.3 mmol, 80% purity, 1.40 eq.) was added as a solid to the reaction mixture at 0°C. The reaction mixture was stirred at 25°C for 16 h. TLC showed that the reaction was complete (5:1 petroleum ether-ethyl acetate, SMR). f (T-03) = 0.61, R f (I-02) = 0.43). The mixture was filtered, the solids were washed with DCM, and the filtrate was collected. The organic filtrate was washed with aqueous NaHSO3 (3x70 mL) and aqueous NaHCO3 (3x 70 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 10:1 petroleum ether-ethyl acetate) to give I-02 (5.78 g, 81% yield) as a colorless oil. 1 HNMR (400MHz, CDCl3) δ4.53 (s, 1H), 3.89-3.49 (m, 4H), 2.93 (brs, 1H), 2.79-2.75 (m, 1H), 2 .50-2.43(m, 1H), 1.80-1.41(m, 6H), 1.19-1.11(m, 6H), 0.90-0.87(m, 18H), 0.00(s, 12H).
[0521] Preparation of (4R)-4-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}pentanal (I-03):
[0522]
[0523] Compound T-03 (3.00 g, 6.54 mmol, 1.00 eq.) was dissolved in DCM (100 mL). Ozone was allowed to bubble into the mixture at -70 ° C for 10 min until the solution turned blue. Oxygen was allowed to bubble into the reaction mixture at -70 ° C for 20 min until the blue solution turned colorless. Triphenylphosphine (5.14 g, 19.6 mmol, 3.00 eq.) was added to the reaction mixture in solid form. The reaction system was stirred at 25 ° C for 16 h. TLC showed that the reaction was complete (5: 1 petroleum ether-ethyl acetate). The solvent was concentrated in vacuo and the residue was purified by column chromatography (silica gel, 5: 1 petroleum ether-ethyl acetate) to obtain I-03 (2.02 g, 67% yield) as a colorless oil. 1H NMR (400MHz, CDCl3) δ9.81 (s, 1H), 4.54 (s, 1H), 3.88-3.50 (m, 4H), 2.60-2.50 ( m, 2H), 1.86-1.76 (m, 4H), 1.18-1.13 (m, 6H), 0.90-0.74 (m, 18H), 0.06 (s, 12H).
[0524] Preparation of (2R, 3R, 5R, 6S)-5-((tert-butyldiphenylsilyl)oxy)-2-(((2R)-5,6-dihydroxyhexan-2-yl)oxy)-6-methyltetrahydro-2H-pyran-3-yl benzoate (I-04):
[0525]
[0526] 4-methylmorpholine N-oxide (0.25mL, 1.05mmol) and osmium tetroxide (0.34mL, 0.0524mmol, 4% weight aqueous solution) are added to a solution of T-05 (0.300g, 0.524mmol) in THF (3mL) and water (1mL). The reaction mixture is stirred for 18h at room temperature in a nitrogen atmosphere. The obtained mixture is quenched with saturated NaHCO3 aqueous solution (2mL), then distributed between ethyl acetate (10mL) and water (5mL). The aqueous layer is extracted with ethyl acetate (2x 10mL). The combined organic layer is dried over magnesium sulfate, filtered, and concentrated. By column chromatography crude product (24g silica gel, 0%-40% acetone in hexane), I-04 (0.280g, 88% yield) is obtained, which is a colorless paste. 1 H NMR (500MHz, CDCl3) δ7.76–7.73 (m, 2H), 7.72–7.65 (m, 4H), 7.58 (ddt, J=8.7, 7.4, 1.3Hz, 1H), 7.43–7.38 (m , 3H), 7.38–7.29 (m, 6H), 4.90 (s, 1H), 4.79 (s, 1H), 3.93–3.85 (m, 2H), 3.84–3.78 (m, 1H), 3.75 (ddt, J=10.1, 6.8, 3.6 Hz, 1H), 3.71-3.64 (m, 1H), 3.58-3.51 (m, 1H), 2.35 (dd, J = 13.0, 4.3 Hz, 1H), 2.10-2.00 (m, 2H), 1.95-1.87 (m, 2H), 1.83-1.69 (m, 2H), 1.69-1.61 (m, 2H), 1.31-1.27 (m, 3H), 1.19 (d, J = 6.1 Hz, 3H), 1.08 (s, 9H). Mass analysis (ESI, +ve) = 607.2 [M+H].
[0527] Preparation of (2R, 3R, 5R, 6S)-5-((tert-butyldiphenylsilyl)oxy)-6-methyl-2-(((R)-5-oxopentan-2-yl)oxy)tetrahydro-2H-pyran-3-yl benzoate (I-05):
[0528]
[0529] To I-04 (0.280g, 0.462mmol) in THF (2mL) and water (2mL) solution NaIO4 (0.224g, 1.05mmol) is added. The reaction mixture is stirred for 18h at room temperature in a nitrogen atmosphere. The obtained mixture is quenched with saturated NaHCO3 aqueous solution (2mL), then distributed between ethyl acetate (10mL) and water (5mL). The aqueous layer is extracted with ethyl acetate (2x 10mL). The combined organic layer is dried over magnesium sulfate, filtered, and concentrated. The crude product is purified by column chromatography (24g silica gel, 0%-30% acetone in hexane), I-05 (0.150g, 57% yield) is obtained, which is a colorless paste. 1 H NMR (500MHz, CDCl3) δ9.89 (t, J=1.6Hz, 1H), 7.76–7.72 (m, 2H), 7.72–7.66 (m, 4H), 7.60–7.56 (m, 1 H), 7.43–7.38(m, 3H), 7.38–7.29(m, 5H), 4.88(td, J=3.2, 2.0Hz, 1H), 4.77(s, 1H), 3.91–3.80(m, 3H), 3.67 (ddd, J = 11.2, 9.1, 4.3 Hz, 1H), 2.64 (dddd, J = 10.9, 8.3, 6.8, 1.6 Hz, 2H), 2.01 (ddd, J = 14.0, 11.2, 3.0 Hz, 1H), 1.96-1.86 (m, 3H), 1.29 (d, J = 6.2 Hz, 3H), 1.19 (d, J = 6.1 Hz, 3H), 1.08 (s, 8H). Mass analysis (ESI, +ve) = 575.1 [M+H].
[0530] Preparation of tert-butyl (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}hept-2-enoate (1):
[0531]
[0532] Compound T-02 (5.00 g, 21.7 mmol, 1.00 eq.) was dissolved in DCM (330 mL), and tert-butyl acrylate (13.9 g, 108 mmol, 15.7 mL, 5.00 eq.) was added to the reaction mixture at 15°C. Grubb M204 catalyst (1.84 g, 2.17 mmol, 0.10 eq.) was added to the reaction system at 15°C, and the mixture was degassed 3 times with nitrogen. The reaction system was heated to 50°C and stirred at 50°C for 16 h. TLC showed that the reaction was complete (5:1 petroleum ether-ethyl acetate, SMR). f (T-02) = 0.50, R f (1) = 0.00). The solvent was concentrated in vacuo and the residue was purified by column chromatography (silica gel, 100% ethyl acetate) and then by preparative HPLC (column: Agela DuraShell C 18 250 x 25 mm, 10 μm; mobile phase A: 0.05% aqueous ammonium hydroxide (v / v), mobile phase B: ACN; gradient B%: 12%-46%, run time: 22 min) to give 1 (2.00 g, 6.05 mmol, 28% yield) as a reddish brown oil. 1 H NMR (400 MHz, CDCl3) δ 6.94-6.87 (m, 1H), 5.79-5.75 (m, 1H), 4.79 (s, 1H), 3.85-3.81 (m, 2H), 3.67-3.62 (m, 2H), 2.32-2.29 (m, 2H), 1.48 (s, 9H), 1.28 (d, J = 6.0 Hz, 3H), 1.15 (d, J = 6.0 Hz, 3H). LCMS analysis (positive mode) = 353.2 [M+Na].
[0533] Preparation of tert-butyl 2-[(3R)-3-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}butyl]cyclopropane-1carboxylate (I-06):
[0534]
[0535] Tert-butyl 2-diethoxyphosphoryl acetate (398 mg, 1.58 mmol, 1.50 eq.) was dissolved in 1,4-dioxane (3.5 mL) and cooled to 15°C. Sodium tert-butoxide (121 mg, 1.26 mmol, 1.20 eq.) was added to the reaction system under a nitrogen atmosphere. The reaction mixture was stirred at 15°C for 1 h. Compound I-03 (500 mg, 1.05 mmol, 1.00 eq.) was added and the mixture was heated at 130°C for 16 h. TLC showed that the reaction was complete (5:1 petroleum ether-ethyl acetate). Acetic acid was added to the mixture to quench the reaction and bring the pH to 7. Brine (2.0 mL) and water (5.0 mL) were added to the mixture, and the reaction system was extracted with ethyl acetate (3x3.0 mL). The layers were separated and the organic layer was washed with aqueous NaHCO3 solution (2x 10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (silica gel, 5:1 petroleum ether-ethyl acetate) to give I-06 (100 mg, 17% yield) as a colorless oil. 1 HNMR (400MHz, CDCl3) δ4.54 (s, 1H), 3.86-3.74 (m, 2H), 3.66-3.56 (m, 2H), 1.80-1.78 (5H), 1.28(s, 9H), 1.30-1.26(m, 2H), 1.19-1.09(m, 6H), 0.90-0.89(m, 18H), 0.68-0.05(m, 12H).
[0536] Preparation of tert-butyl 2-[(3R)-3-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}butyl]cyclopropane-1carboxylate (2):
[0537]
[0538] Compound I-06 (500 mg, 872 μmol, 1.00 eq.) was dissolved in THF (3.5 mL), and Et3N·3HF (1.41 g, 8.73 mmol, 1.42 mL, 10.0 eq.) was added to the reaction mixture at 15°C. The reaction system was stirred at 50°C for 16 h. LCMS showed that the reaction was complete. NaHCO3 aqueous solution was added to bring the pH to 8, and the mixture was concentrated in vacuo. The residue was purified by column chromatography (silica gel, 5:1 petroleum ether-ethyl acetate) to give 2 (130 mg, 43% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 4.70 (s, 1H), 3.84-3.80 (m, 2H), 3.66-3.58 (m, 2H), 2.10-2.01 (m, 1H), 1.87-1.76 (m, 2H), 1.71-1.51 (m, 4H), 1.44 (s, 9H), 1.35-1.19 (m, 6H), 1.15-1.03 (m, 4H), 0.66-0.56 (m, 1H). LCMS analysis (positive mode) = 367.2 [M+Na].
[0539] Preparation of (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}hept-2-enoic acid methyl ester (I-07):
[0540]
[0541] Compound T-03 (10.0 g, 21.8 mmol, 1.00 eq.) was dissolved in DCM (300 mL), and methyl acrylate (9.38 g, 108 mmol, 9.81 mL, 5.00 eq.) was added to the reaction mixture at 25°C. Grubb M204 catalyst (1.85 g, 2.18 mmol, 0.10 eq.) was added to the reaction mixture at 25°C, and then the mixture was heated to 50°C. The reaction mixture was stirred at 50°C for 16 h. TLC showed that the reaction was complete (5:1 petroleum ether-ethyl acetate, SMR). f (T-03) = 0.61, R f (I-07) = 0.44). The solvent was concentrated in vacuo and the residue was purified by column chromatography (silica gel, 5:1 petroleum ether-ethyl acetate) to give I-07 (8.3 g, 74% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl3) δ 6.97-6.80 (m, 1H), 5.79 (d, J = 15.6 Hz, 1H), 4.48 (s, 1H), 4.07-4.03 (m, 2H), 3.71 (s, 3H), 3.59-3.45 (m, 2H), 2.31-2.22 (m, 2H), 1.74-1.69 (m, 4H), 1.19 (d, J = 7.2 Hz, 3H), 1.12 (d, J = 6.0 Hz, 3H), 0.84-0.83 (m, 18H), 0.01-0.00 (m, 12H). LCMS analysis (positive mode) = 539.3 [M+Na].
[0542] Preparation of (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}hept-2-enoic acid (I-08):
[0543]
[0544] Compound I-07 (8.30 g, 16.0 mmol, 1.00 eq.) was dissolved in a mixture of methanol (83 mL), water (41.5 mL) and THF (58 mL). A solution of LiOH·H2O (1.35 g, 32.1 mmol, 2.00 eq.) in water (41.5 mL) was added to the mixture at 25°C. The reaction system was stirred at 50°C for 3 h. TLC showed that the reaction was complete (5:1 petroleum ether-ethyl acetate, SMR f (I-07) = 0.8, R f (I-08) = 0.17). 1N HCl was added to the reaction mixture to pH = 2. The mixture was extracted with ethyl acetate (3 x 30 mL). The layers were separated and the organic layer was washed with brine (40 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to afford I-08 (7.3 g, crude) as a brown oil, which was used directly without further purification.
[0545] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}hept-2-enoic acid cyclohexylmethyl ester (I-09):
[0546]
[0547] Compound I-08 (1.00 eq.) and alcohol (3.00 eq.) were dissolved in DCM (3.5 mL). DCC (1.10 eq.) and DMAP (0.80 eq.) were added to the solution in solid form, and the reaction mixture was stirred at 25 ° C for 16 h. TLC showed that the reaction was complete (5:1 petroleum ether-ethyl acetate). The solvent was concentrated in vacuo and the residue was purified by column chromatography (silica gel, petroleum ether-ethyl acetate) to give I-09 as a yellow oil, which was used directly in the final deprotection step. 1H NMR (400MHz, CDCl3) δ6.97-6.91 (m, 1H), 5.82 (d, J=15.6Hz, 1H), 4.48 (s, 1H), 3.88-3.47 (m, 6H ), 2.29-2.11(m, 2H), 1.74-1.65(m, 9H), 1.25-0.80(m, 14H), 0.84-0.83(m, 18H), 0.00(s, 12H).
[0548] The following compounds were prepared using the above method:
[0549] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}hept-2-enoic acid benzyl ester (I-10):
[0550]
[0551] Yellow oil. 1 H NMR (400MHz, CDCl3) δ7.31-7.28 (m, 5H), 7.02-6.96 (m, 1H), 5.84 (d, J=15.6Hz, 1H), 5.11 (s, 2H), 4.48-4.47 (m, 1H), 3.75-3 .70(m, 2H), 3.59-3.46(m, 2H), 2.30-2.22(m, 2H), 1.74-1.65(m, 4H), 1.20-1.02(m, 8H), 0.84-0.82(m, 18H), 0.00(s, 12H).
[0552] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}hept-2-enoic acid pyridin-3-ylmethyl ester (I-11):
[0553]
[0554] Yellow oil. 1H NMR (400MHz, CDCl3) δ8.58-8.51 (m, 2H), 7.66-7.64 (m, 1H), 7.26-7.22 (m, 1H), 7.01-6.95 (m, 1H), 5.83 (d, J=16.0Hz, 1H), 5.11 (s, 2H), 4.48-4 .47(m, 1H), 3.75-3.70(m, 2H), 3.59-3.48(m, 2H), 2.31-2.23(m, 1H), 1 .74-1.68(m, 4H), 1.20-1.02(m, 9H), 0.84-0.68(m, 18H), 0.00(s, 12H).
[0555] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}hept-2-enoic acid pyridin-4-ylmethyl ester (I-12):
[0556]
[0557] Yellow oil. 1 H NMR (400MHz, CDCl3) δ8.55-8.53 (m, 2H), 7.15-7.10 (m, 2H), 7.03-7.69 (m, 1H), 5.88 (d, 15.6Hz, 1H), 5.11 (s, 2H), 4.48-4.47 (m, 1H) , 3.76-3.70(m, 2H), 3.60-3.49(m, 2H), 2.35-2.26(m, 2H), 1.74-1.69(m, 4H), 1.19-1.03(m, 8H), 0.84-0.68(m, 18H), 0.00(s, 12H).
[0558] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}hept-2-enoic acid 2-phenylethyl ester (I-13):
[0559]
[0560] Yellow oil. 1H NMR (400MHz, CDCl3) δ7.26-7.20 (m, 2H), 7.18-7.14 (m, 3H), 6.93-6.89 (m, 1H), 5.77 (d, J=15.6Hz, 1H), 4.48-4.47 (m, 1H), 4.29-4.22 (m, 2H), 3.7 3-3.70(m, 2H), 3.58-3.49(m, 2H), 2.92-2.86(m, 3H), 2.31-2.11(m, 2H), 1.75-1.51(m, 4H), 1.15-1.01(m, 8H), 0.84-0.68(m, 18H), 0.00(s, 12H).
[0561] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}hept-2-enoic acid cyclohexylmethyl ester (3):
[0562]
[0563] Compound I-09 (1.00 eq.) was dissolved in THF (7 V) and Et3N·3HF (10 eq.) was added. The reaction system was stirred at 50°C for 4 h. LCMS showed that the reaction was complete. The solvent was concentrated in vacuo and the residue was purified by preparative HPLC (column: Phenomena Luna C 18 200mm x 40mm, 10μm; mobile phase A: water w / 0.2% formic acid, mobile phase B: ACN; gradient B%: 30%-70%; run time: 8min) to give a crude product. The crude product was purified by SFC. The crude product was purified by SFC (instrument: Thar SFC80 preparative SFC; column: REGIS (S,S) WHELK-O1 (250mm x 30mm, 10μm); mobile phase A: supercritical CO2, mobile phase B: ethanol; isocratic: B% = 30%; flow rate: 55mL / min; wavelength: 220nm; column temperature: 40°C. System back pressure: 100 bar; run time: 10min) to give 26.0mg of 3 as a colorless oil. 1H NMR (400MHz, CDCl3) δ7.00 (dt, J=15.6, 7.0Hz, 1H), 5.85 (d, J=15.6Hz, 1H), 4.70 (s, 1H), 3.94 (d, J=6.4Hz, 2H), 3.87-3.77 (m, 4H), 3.67-3.52 (m, 2 H), 2.42-2.27(m, 2H), 2.17-2.02(m, 1H), 1.82-1.57(m, 10H), 1.28(d, J= 6.4Hz, 3H), 1.26-1.17 (m, 2H), 1.16 (d, J=6.4Hz, 3H), 1.07-0.92 (m, 2H). LCMS analysis (positive mode) = 393.2 [M+Na]; 98.9% LCMS purity.
[0564] The following compounds were prepared using the above method:
[0565] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}hept-2-enoic acid benzyl ester (4):
[0566]
[0567] Compound 4: 6.5 mg colorless oil. 1 H NMR (400 MHz, CDCl3) δ 7.38-7.32 (m, 5H), 7.05 (dt, J = 15.6, 7.5 Hz, 1H), 5.90 (d, J = 15.6 Hz, 1H), 5.18 (s, 2H), 4.69 (s, 1H), 3.86-3.80 (m, 2H), 3.63-3.54 (m, 2H), 2.35-2.31 (m, 2H), 2.06 (d, J = 13.2 Hz, 1H), 1.81-1.56 (m, 5H), 1.26 (d, J = 6.0 Hz, 3H), 1.15 (d, J = 6.0 Hz, 3H). LCMS analysis (positive mode) = 387.2 [M+Na]; 92.7% LCMS purity.
[0568] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}hept-2-enoic acid pyridin-3-ylmethyl ester (5):
[0569]
[0570] Compound 5: 26.1 mg colorless oil. 1H NMR (400MHz, CDCl3) δ8.64 (d, J=1.6Hz, 1H), 8.59-8.57 (m, 1H), 7.71 (dd, J=6.0, 2.0H z, 1H), 7.30 (dd, J=7.6, 4.3Hz, 1H), 7.07 (dm, J=15.6Hz, 1H), 5.88 (dd, J=15.6, 1.6Hz, 3H). LCMS analysis (positive mode) = 366.2 [M+H]; 98.3% LCMS purity.
[0571] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}hept-2-enoic acid pyridin-4-ylmethyl ester (6):
[0572]
[0573] Compound 6: 26.4 mg colorless oil. 1 H NMR (400MHz, CDCl3) δ8.604 (d, J=4.8Hz, 2H), 7.268 (d, J=4.0Hz, 2H), 7.11 (dt, J=15.6, 7.0Hz, 1H), 5.943 (d, J=14.4Hz, 1H), 5.192 (s, 2H), 4.709 (s , 1H), 3.89-3.81(m, 2H), 3.66-3.59(m, 2H), 2.47-2.32(m, 2H), 2.12-2.0 4 (m, 1H), 1.87-1.64 (m, 5H), 1.27 (d, J=6.0Hz, 3H), 1.16 (d, J=6.0Hz, 3H). LCMS analysis (positive mode) = 366.2 [M+H]; 99.7% LCMS purity.
[0574] Compound (2E,6R)-6-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}hept-2-enoic acid 2-phenylethyl ester (7):
[0575]
[0576] Compound 7: 26.1 mg colorless oil 1H NMR (400MHz, CDCl3) δ7.33-7.22 (m, 5H), 7.00 (dd, J=15.6, 7.8Hz, 1H), 5.84 (d, J=15.6Hz, 1H), 4.70 (s, 1H), 4.35 (t, J=7.2Hz, 2H), 3.84-3.84 (m, 2H), 3.63-3.57 (m, 2H), 2.97 (t, J=7.2Hz, 2H), 2.30-2.20 (m, 2H), 2.08 (d, J=12 .8Hz, 1H), 1.83-1.45 (m, 5H), 1.27 (d, J=6.0Hz, 3H), 1.16 (d, J=6.0Hz, 3H). LCMS analysis (positive mode) = 401.2 [M+Na]; 87.1% LCMS purity.
[0577] Preparation of (2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-2-(((R,E)-7-isopropoxy-7-oxohept-5-en-2-yl)oxy)-6-methyltetrahydro-2H-pyran-3-yl benzoate (I-14):
[0578]
[0579] Using the same method as for preparing I-07, isopropyl acrylate (0.090 mL, 0.699 mmol) and Grubb M204 catalyst (0.015 g, 0.0174 mmol) were added to a solution of T-05 (0.200 g, 0.349 mmol) in DCM (5 mL). After separation and purification, I-14 (0.130 g, 57% yield) was obtained as a colorless paste. 1H NMR (500MHz, CDCl3) δ7.76–7.73 (m, 2H), 7.72–7.66 (m, 4H), 7.58 (ddt, J=8.7, 7.1, 1.3Hz, 1H), 7.44–7.38 (m, 3H), 7.38–7.29 (m, 5H ), 7.04 (dt, J=15.7, 6.8Hz, 1H), 5.90 (dt, J=15.7, 1.6Hz, 1H), 5.10 (p, J=6.3Hz, 2H), 4.89 (dt, J=4.5, 2.1Hz, 1H), 4.77 (s, 1H), 3.91 =-3.80 (m, 2H), 3.68 (ddd, J = 11.2, 9.2, 4.3 Hz, 1H), 2.51-2.25 (m, 3H), 2.04 (ddd, J = 14.0, 11.2, 3.0 Hz, 2H), 1.90 (dt, J = 14.0, 3.8 Hz, 1H), 1.79 (dddd, J = 13.4, 9.4, 5.7, 3.8 Hz, 1H), 1.72-1.63 (m, 1H), 1.29 (dd, J = 6.3, 5.1 Hz, 9H), 1.17 (d, J = 6.1 Hz, 3H), 1.08 (s, 9H). Mass analysis (ESI, +ve) = 660.2 [M+H].
[0580] Preparation of isopropyl (R,E)-6-(((2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hept-2-enoate (I-15):
[0581]
[0582] 1% NaOH aqueous solution (2.3mL, 0.591mmol) is added to a solution of I-14 (0.130g, 0.197mmol) in isopropanol (5mL). The reaction mixture is stirred for 18h at room temperature in a nitrogen atmosphere. The resulting mixture is distributed between ethyl acetate (10mL) and water (5mL). The aqueous layer is extracted with ethyl acetate (2x 10mL). The combined organic layer is dried over magnesium sulfate, filtered, and concentrated. The crude product is purified by column chromatography (24g silica gel, 0%-30% acetone in hexane), I-15 (0.060g, 55% yield) is obtained as a colorless oil. 1H NMR (500MHz, CDCl3) δ7.75–7.66 (m, 4H), 7.48–7.43 (m, 2H), 7.43–7.37 (m, 4H), 7.02 (dt, J=15.6 , 6.8Hz, 1H), 5.89 (dt, J=15.6, 1.6Hz, 1H), 5.10 (p, J=6.3Hz, 1H), 4.63–4.58 (m, 1H), 3.82 (ddd, J = 7.8, 6.3, 5.1 Hz, 1H), 3.77 (dd, J = 8.9, 6.2 Hz, 1H), 2.45-2.27 (m, 3H), 1.90-1.71 (m, 4H), 1.69-1.61 (m, 2H), 1.29 (d, J = 6.3 Hz, 6H), 1.19 (d, J = 6.2 Hz, 3H), 1.14 (d, J = 6.1 Hz, 3H), 1.08 (s, 9H). Mass analysis (ESI, +ve) = 555.1 [M+H].
[0583] Preparation of isopropyl (R,E)-6-(((2R,3R,5R,6S)-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hept-2-enoate (8):
[0584]
[0585] To a solution of I-15 (0.055 g, 0.099 mmol) in THF (3 mL), a solution of 1.0 M TBAF in THF (0.500 mmol, 0.500 mL) was added. The reaction mixture was stirred at room temperature in a nitrogen atmosphere for 18 h. The resulting mixture was concentrated and the crude product was purified by column chromatography (24 g silica gel, 0%-15% MeOH in DCM) to give 8 (0.013 g, 42% yield) as a colorless oil. 1H NMR (500MHz, CDCl3) δ7.01 (dt, J=15.7, 6.8Hz, 1H), 5.84 (dt, J=15.6, 1.6Hz, 1H), 5.08 (p, J=6.2Hz, 1H), 4 .77–4.69 (m, 1H), 3.90–3.85 (m, 1H), 3.83 (q, J=2.9Hz, 1H), 3.70–3.65 (m, 1H), 3.60 (ddd, J=11.0, 9.1, 4. 4 Hz, 1H), 2.34 (ttd, J = 8.5, 6.8, 1.7 Hz, 2H), 2.10 (dddd, J = 13.0, 4.5, 3.5, 1.0 Hz, 1H), 1.85 (ddd, J = 13.2, 10.9, 3.0 Hz, 2H), 1.78-1.69 (m, 3H), 1.30 (d, J = 6.1 Hz, 3H), 1.28 (d, J = 6.3 Hz, 6H), 1.18 (d, J = 6.1 Hz, 3H). Mass analysis (ESI, +ve) = 317.2.1 [M+H].
[0586] Preparation of (2R,3R,5R,6S)-2-(((2R)-7-(tert-butoxy)-5-hydroxy-7-oxohept-2-yl)oxy)-5-((tert-butyldiphenylsilyl)oxy)-6-methyltetrahydro-2H-pyran-3-yl benzoate (I-16):
[0587]
[0588] To a oven dried 25-mL 3-neck round bottom flask equipped with a cryostat and nitrogen inlet was added tert-butyl acetate (0.140 mL, 1.044 mmol) and THF (5 mL). The resulting mixture was cooled to -75 °C and then 1.96 M LDA (0.400 mL, 0.783 mmol) was added dropwise via syringe. The reaction mixture was stirred at -75 °C for 2 h and then (2R, 3R, 5R, 6S)-5-((tert-butyldiphenylsilyl)oxy)-6-methyl-2-(((R)-5-oxopentan-2-yl)oxy)tetrahydro-2H-pyran-3-yl benzoate (0.150 g, 0.261 mmol) in THF (3 mL) was added dropwise via syringe. The reaction mixture was stirred for an additional hour and then quenched with saturated aqueous ammonium chloride solution (1 mL), warmed to room temperature and partitioned between ethyl acetate (10 mL) and water (5 mL). The aqueous layer was extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (24 g silica gel, 0%-30% acetone in hexanes) to afford I-16 (0.090 g, 50% yield). 1HNMR (500MHz, CDCl3) δ7.76–7.72(m, 2H), 7.72–7.66(m, 4H), 7.60–7.55(m, 1H), 7.43–7.38(m, 3H), 7.37–7.29(m, 5H), 4 .89 (d, J=3.6Hz, 1H), 4.77 (s, 1H), 4.10–3.99 (m, 2H), 3.93–3.79 (m, 3H), 3.67 (tdd, J=9.1, 4.2, 2.3Hz, 1H), 3.27 (s, 1H) , 2.52 (ddd, J = 16.4, 4.7, 3.0 Hz, 1H), 2.42 (ddd, J = 16.4, 9.1, 0.8 Hz, 1H), 2.03 (dt, J = 11.3, 3.0 Hz, 1H), 1.89 (dt, J = 13.7, 3.7 Hz, 1H), 1.80-1.63 (m, 4H), 1.51 (d, J = 1.5 Hz, 9H), 1.28 (dd, J = 6.3, 3.2 Hz, 3H), 1.17 (d, J = 6.1 Hz, 3H), 1.08 (s, 9H). Mass analysis (ESI, +ve) = 691.2 [M+H].
[0589] Preparation of tert-butyl (6R)-6-(((2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-3-hydroxyheptanoate (I-17):
[0590]
[0591] Using the same method as for preparing I-15, 1% NaOH aqueous solution (0.520 mL, 0.520 mmol) was added to a solution of I-16 (0.090 g, 0.130 mmol) in methanol (3 mL). After separation and purification, I-17 (0.035 g, 46% yield) was obtained as a colorless paste. 1H NMR (300MHz, CDCl3) δ8.13–8.07 (m, 1H), 7.71–7.59 (m, 5H), 7.48 (dd, J=8.4, 6.9Hz, 2H), 7.39 ( dp, J=9.3, 6.1, 4.9Hz, 5H), 4.59 (s, 1H), 4.01 (s, 1H), 3.76 (dd, J=14.1, 7.1Hz, 2H), 3.64 (d, J=1 3.4 Hz, 2H), 2.49-2.32 (m, 2H), 2.17 (d, J = 0.6 Hz, 2H), 1.88-1.73 (m, 2H), 1.62 (ddd, J = 21.8, 11.3, 5.7 Hz, 5H), 1.47 (t, J = 0.9 Hz, 9H), 1.15 (d, J = 6.2 Hz, 3H), 1.11 (d, J = 6.1 Hz, 3H), 1.05 (s, 9H). Mass analysis (ESI, +ve) = 587.1 [M+H].
[0592] Preparation of tert-butyl (6R)-6-(((2R,3R,5R,6S)-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-3-hydroxyheptanoate (9):
[0593]
[0594] To a solution of I-17 (0.035 g, 0.060 mmol) in THF (2 mL) was added 1.0 M TBAF (0.30 mmol, 0.300 mL) in THF. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 18 h. The resulting mixture was concentrated and the crude product was purified by column chromatography (24 g silica gel, 0%-15% MeOH in DCM) to give 9 (0.015 g, 75%) as a colorless oil. 1H NMR (500MHz, CDCl3) δ4.76–4.70 (m, 1H), 4.07–3.99 (m, 1H), 3.91–3.80 (m, 2H), 3.72–3.65 (m, 1 H), 3.60 (dddd, J=11.4, 9.1, 4.6, 2.4Hz, 1H), 3.36–3.30 (m, 1H), 2.44 (t, J=3.3Hz, 1H), 2.39 (dd , J = 8.9, 3.6 Hz, 1H), 2.13-2.07 (m, 1H), 1.85 (dddd, J = 13.2, 11.1, 3.0, 2.1 Hz, 2H), 1.73-1.64 (m, 3H), 1.63-1.55 (m, 2H), 1.49 (s, 9H), 1.30 (dd, J = 6.2, 3.6 Hz, 3H), 1.17 (dd, J = 6.1, 1.8 Hz, 3H). Mass analysis (ESI, +ve) = 349.1 [M+H].
[0595] Preparation of (2R,3R,5R,6S)-2-(((R,E)-7-(tert-butoxy)-7-oxohept-5-en-2-yl)oxy)-5-((tert-butyldiphenylsilyl)oxy)-6-methyltetrahydro-2H-pyran-3-yl benzoate (I-18):
[0596]
[0597] Using the same method as for preparing I-09, tert-butyl acrylate (0.230 mL, 1.572 mmol) and Grubb M204 catalyst (0.025 g, 0.0262 mmol) were added to a solution of T-05 (0.300 g, 0.524 mmol) in DCM (5 mL). After separation and purification, I-18 (0.300 g, 85% yield) was obtained as a colorless paste. 1H NMR (500MHz, CDCl3) δ7.79–7.76 (m, 2H), 7.75–7.69 (m, 4H), 7.61 (ddt, J=8.7, 7.1, 1.3Hz, 1H), 7.46–7.41 (m, 3H), 7.40–7 .33(m, 5H), 6.98(dt, J=15.6, 6.8Hz, 1H), 5.88(dt, J=15.6, 1.6Hz, 1H), 4.92(s, 1H), 4.80(s, 1H), 3.94–3.84(m, 2H), 3.71 (ddd, J = 11.1, 9.1, 4.3 Hz, 1H), 2.49-2.31 (m, 3H), 2.08 (ddd, J = 14.0, 11.2, 2.9 Hz, 1H), 1.94 (dt, J = 13.4, 3.8 Hz, 1H), 1.87-1.78 (m, 1H), 1.71 (ddd, J = 13.3, 9.2, 5.0 Hz, 1H), 1.56 (s, 9H), 1.33 (d, J = 6.2 Hz, 3H), 1.21 (d, J = 6.1 Hz, 3H), 1.12 (s, 9H). Mass analysis (ESI, +ve) = 673.1 [M+H].
[0598] Preparation of tert-butyl (R,E)-6-(((2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hept-2-enoate (I-19):
[0599]
[0600] Using the same method as for the preparation of 1-15, 1% aqueous NaOH solution (3.5 mL, 0.892 mmol) was added to a solution of 1-18 (0.300 g, 0.446 mmol) in MeOH (5 mL) to obtain 1-19 (0.170 g, 67% yield) as a colorless oil after separation and purification. 1HNMR (500MHz, CDCl3) δ7.74–7.67 (m, 4H), 7.48–7.37 (m, 6H), 6.93 (dt, J=15.6, 6.8 Hz, 1H), 5.83 (dt, J=15.6, 1.6Hz, 1H), 4.61 (d, J=1.6Hz, 1H), 3.84–3.75 (m, 2H), 3. 69–3.62 (m, 2H), 2.43–2.26 (m, 3H), 1.89–1.80 (m, 2H), 1.78–1.71 (m, 1H), 1.68–1.62 (m, 1H), 1.51 (s, 9H), 1.19 (d, J=6.2 Hz, 3H), 1.14 (d, J=6.1 Hz, 3H), 1.08 (s, 9H). Mass analysis (ESI, +ve) = 569.2 [M+H].
[0601] Preparation of tert-butyl (R)-6-(((2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)heptanoate (I-20):
[0602]
[0603] Pd / C (0.015 g, 0.0105 mmol, 10% wt wet form) was added to a solution of 1-19 (0.060 mL) in methanol (3 mL) connected to a 3-way valve. The reaction mixture was first evacuated and then purged with nitrogen - this evacuation-then-nitrogen purge procedure was repeated 3 times to ensure that there was only nitrogen in the flask. After the final evacuation, a hydrogen balloon was connected to the 3-way valve. The reaction mixture was stirred at room temperature under a hydrogen atmosphere for 18 h. The resulting mixture was filtered through a pad of Celite(R). The filtrate was concentrated in vacuo to afford 1-20 (0.045 g, 74% yield). 1H NMR (500MHz, CDCl3) δ7.73–7.66(m, 4H), 7.46–7.42(m, 2H), 7.42–7.37(m, 4H), 4.60(s, 1H), 3.83–3.76 (m, 2H), 3.65 (dq, J=9.0, 4.8Hz, 2H), 3.52 (s, 2H), 2.32–2.25 (m, 2H), 1.8 7 (ddd, J = 13.6, 10.7, 3.0 Hz, 1H), 1.83-1.77 (m, 1H), 1.71-1.61 (m, 3H), 1.50 (d, J = 0.5 Hz, 2H), 1.48 (s, 9H), 1.19 (d, J = 6.2 Hz, 3H), 1.12 (d, J = 6.1 Hz, 3H), 1.08 (d, J = 1.9 Hz, 9H). Mass analysis (ESI, +ve) = 571.2 [M+H].
[0604] Preparation of (R)-tert-butyl 6-(((2R,3R,5R,6S)-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)heptanoate (10):
[0605]
[0606] To a solution of I-20 (0.045 g, 0.079 mmol) in THF (2 mL) was added a solution of 1.0 M TBAF in THF (0.35 mmol, 0.350 mL). The reaction mixture was stirred at room temperature in a nitrogen atmosphere for 18 h. The resulting mixture was concentrated and the crude product was purified by column chromatography (24 g silica gel, 0%-15% MeOH in DCM) to give 10 (0.012 g, 46% yield) as a light brown paste. 1 H NMR (500MHz, CDCl3) δ4.75–4.71 (m, 1H), 3.89–3.79 (m, 3H), 3.72 (dd, J=9.2, 6. 2Hz, 1H), 3.59 (ddd, J=11.4, 9.2, 4.7Hz, 1H), 3.38 (d, J=3.5Hz, 1H), 2.25 (t, J=7 .3 Hz, 2H), 2.15-2.07 (m, 1H), 1.86 (ddd, J = 13.1, 11.3, 3.0 Hz, 2H), 1.67-1.61 (m, 3H), 1.60-1.54 (m, 2H), 1.46 (s, 9H), 1.32-1.29 (m, 3H), 1.15 (d, J = 6.1 Hz, 3H). Mass analysis (ESI, +ve) = 333.2 [M+H].
[0607] Preparation of (2R, 3R, 5R)-2-(((E)-6-(tert-butoxy)-6-oxohex-4-en-1-yl)oxy)-6-methyltetrahydro-2H-pyran-3,5-diyl dibenzoate (I-21):
[0608]
[0609] Using the same method as for preparing I-07, tert-butyl acrylate (0.205 mL, 1.41 mmol) and Grubb M204 catalyst (0.020 g, 0.0235 mmol) were added to a solution of T-04 (0.200 g, 0.471 mmol) in DCM (5 mL). After separation and purification, I-21 (0.180 g, 73% yield) was obtained. 1 H NMR (300MHz, CDCl3) δ8.17–8.10 (m, 2H), 8.09–8.02 (m, 2H), 7.61 (td, J=7.3, 1.7Hz, 2H), 7.54–7.41 (m, 4H), 6.92 (dt, J=14.6, 6.9Hz, 1H), 5.83 (d, J=16.0Hz, 1H), 5.27–5.13 (m, 2H), 4.84 (s, 1H), 4.07 ( dd, J = 9.9, 6.1 Hz, 1H), 3.81 (dt, J = 9.9, 6.5 Hz, 1H), 3.55 (dt, J = 9.9, 6.1 Hz, 1H), 2.44 (d, J = 13.9 Hz, 1H), 2.35 (q, J = 7.2 Hz, 2H), 2.28-2.14 (m, 1H), 1.91-1.78 (m, 2H), 1.50 (s, 8H), 1.32 (d, J = 6.2 Hz, 3H). Mass analysis (ESI, +ve) = 525.1 [M+H].
[0610] Preparation of tert-butyl (E)-6-(((2R,3R,5R)-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hex-2-enoate (11):
[0611]
[0612] To a solution of 1-21 (0.180 g, 0.344 mmol) in methanol (2 mL) was added KCO (0.014 g, 0.103 mmol). The reaction mixture was stirred at room temperature under nitrogen atmosphere for 18 h. The resulting mixture was concentrated and the crude product was purified by column chromatography (24 g silica gel, 0%-15% MeOH in DCM) to give 11 (0.070 g, 70% yield). 1H NMR (500MHz, CDCl3) δ6.90 (dt, J=15.6, 7.0Hz, 1H), 5.79 (dt, J=15.6, 1.6Hz, 1H), 4.59 (d, J=1.7Hz, 1H), 3.88 (s, 1H), 3.79–3.71 (m, 1H), 3.68–3 .57 (m, 2H), 3.48 (dt, J=9.8, 5.9Hz, 1H), 2.31 (qd, J=7.2, 1.6Hz, 2H), 2. 14–2.07 (m, 1H), 1.92–1.75 (m, 4H), 1.51 (s, 8H), 1.32 (d, J=5.9Hz, 3H). Mass analysis (ESI, +ve) = 317.2 [M+H].
[0613] Preparation of (2E)-6-{[(2S,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}-6-methylhept-2-enoic acid tert-butyl ester (I-22):
[0614]
[0615] To the stirred solution of T-07 (0.75mmol) in DCM (5mL), tert-butyl acrylate (1.50mmol) and Grubb M204 catalyst (0.035mmol) were added. The mixture was stirred for 18h at room temperature in a nitrogen atmosphere. The reaction was quenched with water (1mL) and then distributed between water (5mL) and DCM (10mL). The organic layer was washed with (5mL), brine (5mL) water, dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (ethyl acetate-hexane) to obtain I-22.
[0616] Preparation of tert-butyl (2E)-6-{[(2S,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-6-methylhept-2-enoate (12):
[0617]
[0618] To a solution of 1-22 (0.2 mmol) in THF (5 mL) was added a 1.0 M TBAF solution in THF (0.500 mmol, 0.500 mL). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 18 h. The resulting mixture was concentrated and the crude product was purified by column chromatography (0%-15% MeOH in DCM) to give 12.
[0619] Preparation of (2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-2-(((R,E)-7-ethoxy-7-oxohept-5-en-2-yl)oxy)-6-methyltetrahydro-2H-pyran-3-yl benzoate (I-23):
[0620]
[0621] To the solution of T-05 (0.420g, 0.734mmol) in DCM (5mL) stirred, ethyl acrylate (0.160mL, 1.470mmol) and Grubb M204 catalyst (0.031g, 0.0367mmol) are added. The reaction mixture is stirred for 18h at room temperature in a nitrogen atmosphere. The reaction mixture is quenched with water (1mL), then distributed between water (5mL) and DCM (10mL). The organic layer is washed with water (5mL), brine (5mL), dried over magnesium sulfate, filtered, and concentrated. By column chromatography purification of the crude product (40g silica gel, 0%-25% ethyl acetate in hexane), I-23 (0.340g, 72% yield) is obtained, which is a clear oil. 1 H NMR (500MHz, CDCl3) δ7.76–7.72 (m, 2H), 7.71–7.66 (m, 4H), 7.60–7.55 (m, 1H), 7.43–7.38 (m, 4H), 7.37–7.30 (m, 6H), 7. 05 (dt, J=15.7, 6.8Hz, 1H), 5.92 (dt, J=15.6, 1.6Hz, 1H), 4.93–4.86 (m, 1H), 4.77 (s, 1H), 4.23 (q, J=7.1Hz, 2H), 3.92–3. 80 (m, 2H), 3.68 (ddd, J = 11.1, 9.1, 4.3 Hz, 1H), 2.48-2.30 (m, 3H), 2.04 (ddd, J = 14.0, 11.2, 3.0 Hz, 1H), 1.93-1.87 (m, 2H), 1.84-1.76 (m, 1H), 1.72-1.64 (m, 1H), 1.33 (t, J = 7.1 Hz, 3H), 1.29 (d, J = 6.2 Hz, 3H), 1.18 (d, J = 6.1 Hz, 3H), 1.09 (s, 9H). Mass analysis (ESI, +ve) = 645.1 [M+H].
[0622] Preparation of (R,E)-6-(((2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)hept-2-enoic acid (I-24):
[0623]
[0624] Lithium hydroxide (0.050 g, 2.11 mmol) and water (2 mL) were added to a stirred solution of I-23 (0.340 g, 0.527 mmol) in 1,4-dioxane (8 mL). The reaction mixture was heated at 60 ° C in a nitrogen atmosphere for 18 h. The reaction mixture was cooled to room temperature and acidified to pH = 5-6 with 1M HCl. The resulting mixture was extracted with a 20% isopropanol chloroform solution (3 x 10 mL). The combined organic layer was washed with brine (5 mL), dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (24 g silica gel, 5%-40% ethyl acetate in hexane containing AcOH) to obtain I-24 (0.220 g, 81% yield) as a white foam. 1 HNMR (500MHz, CDCl3) δ7.74–7.67 (m, 4H), 7.49–7.43 (m, 2H), 7.40 (tdd, J=8.1, 6.6, 1.1Hz, 4H), 7 .16 (dt, J=15.7, 6.8Hz, 1H), 5.93 (dt, J=15.7, 1.6Hz, 1H), 4.62 (d, J=1.8Hz, 1H), 3.87–3.80 (m, 1 H), 3.79-3.73 (m, 1H), 3.71-3.62 (m, 2H), 2.41 (ddq, J = 31.7, 15.7, 8.4 Hz, 3H), 1.90-1.81 (m, 2H), 1.80-1.73 (m, 2H), 1.72-1.63 (m, 2H), 1.19 (d, J = 6.3 Hz, 3H), 1.15 (d, J = 6.1 Hz, 3H), 1.08 (s, 9H). Mass analysis (ESI, +ve) = 513.2 [M+H].
[0625] Preparation of (R,E)-6-(((2R,3R,5R,6S)-5-((tert-butyldiphenylsilyl)oxy)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1-(pyrrolidin-1-yl)hept-2-en-1-one (I-25):
[0626]
[0627] DIPEA (0.130 mL, 0.732 mmol), pyrrolidine (0.040 mL, 0.439 mmol), EDCI (0.065 mL, 0.293 mmol) and HOBT (0.056 g, 0.366 mmol) were added to the stirred solution of I-24 (0.075 g, 0.146 mmol) in DCM (3 mL). The reaction mixture was stirred for 18 h at room temperature in a nitrogen atmosphere. The reaction mixture was quenched (1 mL) with saturated aqueous ammonium chloride solution and then distributed between water (5 mL) and DCM (10 mL). The aqueous layer was extracted with a 20% isopropanol chloroform solution (2x5 mL). The combined organic layer was dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (24 g silica gel, 10%-40% acetone in hexane) to obtain I-25 (0.035 g, 40% yield), which was a clear oil. 1 H NMR (500MHz, CDCl3) δ7.73–7.67 (m, 4H), 7.47–7.42 (m, 2H), 7.42–7.37 (m, 4H), 7.00 (dt, J=15.1, 6.9Hz, 1H), 6 .18 (dt, J=15.1, 1.6Hz, 1H), 4.60 (d, J=1.8Hz, 1H), 3.85–3.76 (m, 2H), 3.69–3.62 (m, 2H), 3.55 (t, J=6.6Hz, 3H ), 2.47–2.37 (m, 1H), 2.36–2.27 (m, 1H), 1.93 (s, 3H), 1.87 (ddd, J=13.5, 10.6, 3.1 Hz, 2H), 1.83–1.74 (m, 3H), 1.65 (dq, J=8.8, 4.7, 3.7 Hz, 1H), 1.32–1.26 (m, 1H), 1.19 (d, J=6.3 Hz, 3H), 1.14 (d, J=6.1 Hz, 3H), 1.07 (s, 9H). Mass analysis (ESI, +ve) = 588.2 [M+Na].
[0628] Preparation of (R,E)-6-(((2R,3R,5R,6S)-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1-(pyrrolidin-1-yl)hept-2-en-1-one (13):
[0629]
[0630] To the stirred solution of I-25 (0.030g, 0.053mmol) in THF (2mL), a solution of 1.0M TBAF in THF (0.27mmol, 0.270mL) was added. The reaction mixture was stirred for 18h at room temperature in a nitrogen atmosphere. The mixture obtained was concentrated. The crude product was purified by column chromatography (24g silica gel, 0%-15% MeOH in DCM), 13 (0.010g, 60% yield) was obtained as a colorless paste. 1 H NMR (500MHz, CDCl3) δ7.06 (dt, J=15.2, 7.0Hz, 1H), 6.14 (dt, J=15.2, 1.6Hz, 1H), 4.74–4.69 (m, 1H), 3.93–3.86 (m, 1H), 3.82 (td, J=3.2, 1.7Hz, 1H), 3.73–3.65 (m, 1H), 3.53 (t, J=6.8Hz, 5H), 2 .37 (qt, J = 7.1, 1.6 Hz, 2H), 2.12 (dddd, J = 13.0, 4.5, 3.3, 1.0 Hz, 1H), 2.01-1.95 (m, 4H), 1.94-1.90 (m, 1H), 1.90-1.85 (m, 2H), 1.78-1.68 (m, 2H), 1.28 (d, J = 6.2 Hz, 3H), 1.18 (d, J = 6.1 Hz, 3H). Mass analysis (ESI, +ve) = 328.1 [M+H].
[0631] Preparation of ethyl (2Z,6R)-6-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}hept-2-enoate (I-26):
[0632]
[0633] Ethyl bis(2,2,2-trifluoroethyl)phosphonoacetate (0.25mmol) and 18-crown-6 (0.25mmol) were dissolved in THF (1.0mL) and cooled to -78°C. A solution of 1.0M KHMDS (0.25mmol) in THF was added and the reaction system was stirred at -78°C for 30min. Aldehyde I-03 (0.15mmol) as a solution in THF (1.0mL) was added and the reaction system was stirred at -78°C for 2h and then warmed to room temperature. The mixture was quenched with aqueous ammonium chloride solution (50mL) and extracted with ethyl acetate (2x50mL). The layers were separated, the organic layer was washed with water (2x 40mL), brine (30mL), the combined organic layer was dried with magnesium sulfate, filtered, and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether-ethyl acetate) to give I-26.
[0634] Preparation of ethyl (2Z,6R)-6-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}hept-2-enoate (14):
[0635]
[0636] To a solution of 1-26 (0.2 mmol) in THF (3 mL) was added a 1.0 M TBAF solution in THF (0.250 mmol, 0.250 mL). The reaction mixture was stirred at room temperature under a nitrogen atmosphere for 18 h. The resulting mixture was concentrated and the crude product was purified by column chromatography (0%-15% MeOH in DCM) to give 14.
[0637] Preparation of ethyl 2-[(3R)-3-{[(2R,3R,5R,6S)-3,5-bis[(tert-butyldimethylsilyl)oxy]-6-methyloxan-2-yl]oxy}butyl]cyclopropane-1-carboxylate (I-27):
[0638]
[0639] A solution of diiodomethane (1.0 mmol) and zinc-copper coupling powder (15 mg) in ether (15 mL) was stirred for 30 min, and then I-26 (0.5 mmol) was added to the solution. After the reaction system was refluxed for 60 hr, the mixture was poured into aqueous ammonium chloride solution (50 mL). The mixture was extracted with ethyl acetate (2 x 50 mL). The layers were separated, and the organic layer was washed with water (2 x 40 mL), thiosulfate aqueous solution (30 mL), and the combined organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo. The crude product was purified by column chromatography (ethyl acetate-hexane) to give I-27.
[0640] Preparation of ethyl 2-[(3R)-3-{[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy}butyl]cyclopropane-1-carboxylate (15):
[0641]
[0642] To a solution of 1-27 (0.1 mmol) in THF (3 mL) was added 1.0 M TBAF in THF (0.150 mmol, 0.150 mL). The reaction mixture was stirred at room temperature under nitrogen for 18 h. The resulting mixture was concentrated and the crude product was purified by column chromatography (0%-15% MeOH in DCM) to give 15.
[0643] Using the above protocol, compounds 16-56 illustrated in Table 3 were prepared.
[0644] Table 3. Ascaroside derivatives
[0645]
[0646]
[0647]
[0648]
[0649]
[0650]
[0651]
[0652]
[0653]
[0654] Example 3
[0655] Stimulation of THP-1 cells: Testing the effects of compound 1 and compound 10
[0656] Compound 1 and Compound 10 significantly reduced IL-6 and TNFα secretion in human cells in vitro. In particular, both Compound 1 and Compound 10 reduced IL-6 and TNFα in stimulated cultures of immortalized mononuclear THP-1 cells.
[0657] Human immortalized monocytic THP-1 cells were maintained in RPMI 1640 medium without phenol red, containing 10% (v / v) fetal bovine serum (FBS), 2mM L-glutamine, penicillin (100 units / mL), streptomycin (100 μg / mL), amphotericin B (2.5 μg / mL) and 50 μM β-mercaptoethanol (BME) at 37°C and 5% (v / v) CO2. THP-1 cells were seeded in 1 mL THP-1 medium (cell culture medium containing 10% (v / v) FBS, 2mM L-glutamine, penicillin (100 units / mL), streptomycin (100 μg / mL), amphotericin B (2.5 μg / mL) and 50 μM BME) / well in 6-well plates at a density of 1 million cells / mL. Cells were differentiated by adding 100 nM phorbol 12-myristate 13-acetate (PMA) to each well and then incubating the cells at 37°C with 5% (v / v) CO2 for 5.5 h. Without removing the culture medium, different concentrations (0, 0.1, 1, 10, 100 or 200 μM) of compound 1 and compound 10 were added to each well. Cells were stimulated by adding 20 ng / mL interferon gamma (IFN-γ) and 100 ng / mL lipopolysaccharide (LPS) to each well within 30 min. After stimulation, THP-1 cells were cultured at 37°C with 5% (v / v) CO2 for 72 h. Supernatants were collected and stored at -80°C until use.
[0658] The IL-6 release from the supernatant collected 72 hours after stimulation was measured using the AlphaLISA Human IL-6 Assay Kit. Figure 1A , 1B , as shown in 2A and 2B. Figure 1A Shown are the fold changes in the levels of IL-6 secreted by THP1-derived macrophages when different concentrations of Compound 1 (with bars labeled "0.1, 1, 10, 100, or 200 μM" representing the concentration) were applied compared to the highest level of IL-6 secreted by THP1-derived macrophages without Compound 1 (which is represented by the bar labeled "0 μM"). Administration of several concentrations of Compound 1 significantly reduced these levels. Figure 1B Shown are the fold changes in the levels of IL-6 secreted by THP1-derived macrophages upon application of different concentrations of Compound 10 (represented by the bars labeled "0.1, 1, 10, 100, or 200 μM") compared to the highest level of IL-6 secreted by THP1-derived macrophages without Compound 10 (represented by the bars labeled "0 μM"). Administration of several concentrations of Compound 10 significantly reduced these levels.
[0659] Figure 2AThe fold change in the level of IL-6 secreted by THP1-derived macrophages when applying different concentrations of ascr#7 (indicated by gray bars labeled "0.1, 1, 10, 100, or 200 μM") or compound 1 (indicated by black bars labeled "0.1, 1, 10, 100, or 200 μM") is shown compared to the highest level of IL-6 secreted by THP1-derived macrophages without compound 1 or ascr#7 (indicated by bars labeled "0 μM"). The application of different concentrations of ascr#7 significantly reduced the level of IL-6, and the use of several concentrations of compound 1 reduced the level of IL-6 even more significantly. Figure 2B The fold change of IL-6 levels secreted by THP1-derived macrophages when applying different concentrations of ascr#7 (which are represented by gray bars marked "0.1, 1, 10, 100, or 200 μM") or compound 10 (which are represented by black bars marked "0.1, 1, 10, 100, or 200 μM") is shown compared to the highest level of IL-6 secreted by THP1-derived macrophages without compound 10 or ascr#7 (which are indicated by bars marked "0 μM"). The application of different concentrations of ascr#7 significantly reduced the level of IL-6, and the level of IL-6 was even more significantly reduced when using several concentrations of compound 10.
[0660] The TNFα release from the supernatant collected 72 hours after stimulation was measured using the AlphaLISA Human TNFα Detection Kit. Figure 3A and 3B as shown in . Figure 3A Shown are the fold changes in the levels of TNFα secreted by THP1-derived macrophages when applying different concentrations of Compound 1 (which are represented by gray bars labeled "0.1, 1, 10, 100, or 200 μM") compared to the highest level of TNFα secreted by THP1-derived macrophages without Compound 1 (which are indicated by bars labeled "0 μM"). Administration of several concentrations of Compound 1 significantly reduced these levels. Figure 3B Shown are the fold changes in the levels of IL-6 secreted by THP1-derived macrophages when applying different concentrations of compound 10 (which are represented by gray bars labeled "0.1, 1, 10, 100, or 200 μM") compared to the highest level of TNFα secreted by THP1-derived macrophages without compound 10 (which are indicated by bars labeled "0 μM"). Administration of several concentrations of compound 10 significantly reduced these levels.
[0661] Example 4
[0662] Stability of compound 1 in hepatocytes
[0663] Compound 1 was provided at 1000x stock solution in dimethyl sulfoxide (DMSO) and diluted to 1 mM with DMSO in a 96-well plate. 30 mM positive compounds (7-ethoxycoumarin and 7-hydroxycoumarin) were provided at 1000x stock solution in DMSO and diluted to 3 mM with DMSO in a 96-well plate. 20 μL of the 1000x stock solution of each compound was pipetted and mixed with 380 μL of 45% MeOH / H2O to obtain a 50 μM compound 1 and a 150 μM positive control compound solution to form a 50x intermediate solution. 20 μL of the 50x intermediate solution of each compound was pipetted and mixed with 450 μL of pre-warmed culture medium to obtain a 5 μM compound 1 and a 15 μM positive control compound solution to form a 5x working solution. The incubation medium was Williams medium E (without phenol red) containing 2 mM L-glutamine and 25 mM HEPES. 10 μL of the 5x working solution of each compound was transferred into the appropriate wells of a 96-well plate at 0, 15, 30, 60 and 90 minutes in duplicate. The plates containing the compounds were incubated at 37°C in an incubator.
[0664] The cell suspension was prepared by thawing the cryopreserved cells, isolating the cells and suspending the cells in a thawing medium. The thawing medium was Williams medium E, which contained 5% fetal bovine serum and 30% Percoll solution and other supplements. The cells were cultured in a pre-warmed incubation medium at 0.625 x 10 6 The cell suspension was diluted to a density of 10 cells / mL. After thawing, cell viability was tested using the trypan blue exclusion method.
[0665] By adding 40 μL of 0.625x10 6 The reaction was initiated by aliquoting the 10 μL suspension of 10 cells / mL into each well of a 96-well plate containing 10 μL of compound solution. The plate containing the samples for 15 minutes, 30 minutes, 60 minutes and 90 minutes was immediately incubated at 37°C with 5% CO2 in an incubator.
[0666] Table 4. Final concentration of each component in the incubation medium.
[0667]
[0668] The 0 minute sample was added with stop solution before adding cells. The stop solution was acetonitrile containing 200 ng / mL tolbutamide and labetalol as internal standards. The 0 minute and 90 minute medium control (MC) sample plates (T0-MC and T90-MC) were incubated with compounds in the incubation medium without cells only using the same conditions as the above time points.
[0669] At each corresponding time point, the reaction was stopped by quenching. The sample plate was immediately vortexed, placed on a shaker at 500 rpm for 10 min, and then the plate was centrifuged at 3220×g for 20 min. 50 μl / well supernatant of the positive control in the sample plate was transferred to another set of 96 deep well plates, which contained 150 μl / well ultrapure water according to the plate map, and 100 μl / well supernatant of the wells containing compound 1 was transferred for LC / MS / MS analysis.
[0670] The remaining percentage of compound 1 after incubation was calculated according to the following formula.
[0671]
[0672] Calculate t using the following first-order kinetic equation 1 / 2 and CL int .
[0673] C t =C0·e -k·t ,
[0674] when hour
[0675] CL int(hep) = k / million cells / ml
[0676] CL int(liver) =CL int(hep) *Liver weight (g / kg body weight) *Hepatocellularity.
[0677] The results are as follows Figure 4 As shown in . The half-life of Ascr#7 in mouse, rat and human hepatocytes is greater than 216.8 minutes. The half-life of compound 1 in rat hepatocytes is 23.1 minutes and the half-life in human hepatocytes is 106 minutes.
[0678] Example 5
[0679] Stability of compound 1 in plasma
[0680] If necessary, the pH of plasma was adjusted to 7.4 ± 0.1. A 1 mM intermediate solution was prepared by diluting 10 μL of a 10 mM stock solution of compound 1 with 90 μL DMSO; a 1 mM intermediate solution of the positive control propantheline bromide was prepared by diluting 10 μL of the stock solution with 90 μL ultrapure water. A 100 μM dosing solution was prepared by diluting 10 μL of a 1 mM intermediate solution with 90 μL 45% MeOH / H2O. 2 μL of 100 μM dosing solution was spiked into 98 μL blank plasma to achieve a final concentration of 2 μM compound in duplicate. The samples were incubated at 37°C in a water bath. At each time point (0, 10, 30, 60, and 120 min), 400 μL of stop solution (200 ng / mL tolbutamide plus 200 ng / mL labetalol in 50% ACN / MeOH) was added and mixed thoroughly to precipitate protein. The sample plate was centrifuged at 4,000 rpm for 10 min. An aliquot of the supernatant (100 μL) was removed from each well and mixed with 200 μL of ultrapure water. The samples were shaken at 800 rpm for approximately 10 min prior to LC / MS / MS analysis.
[0681] The remaining percentage of compound 1 (test article) after incubation was calculated according to the following equation.
[0682]
[0683] The results are as follows Figure 5A and 5B As shown in . After 120 minutes, ascr#7 remained 103.4%, 99.8% and 89.8% in mouse, rat and human plasma, respectively. After 120 minutes, compound 1 remained 19.2% and 86.5% of compound 1 in rat and human plasma, respectively.
[0684] Example 6
[0685] Bidirectional permeability of compound 1 in Caco-2 cells
[0686] Caco-2 cells purchased from ATCC were cultured at 1 × 10 5 Cells / cm 2 The cells were seeded onto polyethylene membrane (PET) in 96-well BD insert plates and the culture medium was refreshed every 4-5 days until a confluent cell monolayer was formed on days 21-28.
[0687] The transport buffer in this study was Hank's balanced salt solution (HBSS) containing 10mM HEPES at pH 7.40±0.05. Compound 1 was tested bidirectionally at 2μM in duplicate. Digoxin was tested bidirectionally at 10μM in duplicate, while nadolol and metoprolol were tested in duplicate at 2μM in the A to B direction. The final dimethyl sulfoxide concentration was adjusted to less than 1%. The plate was incubated in an incubator at 37±1°C, 5% CO2 and saturated humidity for 2 hours without shaking. All samples mixed with acetonitrile containing internal standard were centrifuged at 4000rpm for 10min. Subsequently, 100μL of supernatant was diluted with 100μL of distilled water for LC / MS / MS analysis. The concentrations of compound 1 and warfarin in the starting solution, donor solution and receiver solution were quantified by the LC / MS / MS method using the peak area ratio of analyte / internal standard.
[0688] After the transport assay, a Lucifer Yellow exclusion assay was performed to determine the integrity of the Caco-2 cell monolayer.
[0689] The apparent permeability coefficient P was calculated using the following formula app (cm / s):
[0690] P app =(dC r / dt)x V r / (A x C0)
[0691] where dC r / dt is the cumulative concentration of the compound in the receiving chamber as a function of time (μM / s); V r is the volume of solution in the receiving chamber (0.075 mL on the apical side and 0.25 mL on the basolateral side); A is the surface area for transport, i.e., 0.0804 cm for a monolayer 2 ; C0 is the initial concentration in the donor chamber (μM).
[0692] The outward flux ratio was calculated using the following formula:
[0693] Outward flux ratio = P app (BA) / P app (AB)
[0694] The percent yield was calculated using the following formula:
[0695] % yield = 100 x [(V r x C r )+(V d x C d )] / (V d x C0)
[0696] Where V dis the volume in the donor chamber (0.075 mL on the apical side and 0.25 mL on the basolateral side); C d and C r are the final concentrations of the transported compound in the donor and receiver compartments, respectively.
[0697] The results are as follows Figure 6 Ascr#7 showed low bidirectional permeability in CaCo-2 cells. Compound 1 showed high bidirectional permeability in CaCo-2 cells.
[0698] Example 7
[0699] Plasma protein binding of compound 1-HTD
[0700] HT-dialysis plates (model HTD 96b, catalog number 1006) and dialysis membranes (molecular weight cutoff 12-14 KDa, catalog number 1101) can be purchased from HT Dialysis LLC (Gales Ferry, CT).
[0701] Plasma was thawed in running cold tap water and centrifuged at 3220 x g for 5 min to remove any clots. The pH value was checked and recorded. Only plasma in the pH 7.0 to pH 8.0 range was used. The dialysis membrane was pretreated according to the manufacturer's instructions. Briefly, the dialysis membrane strips were soaked in ultrapure water at room temperature for about 1 hr. Thereafter, each membrane strip containing 2 membranes was separated and soaked in ethanol: water (20:80 v:v) for about 20 min. The membrane was rinsed and soaked in ultrapure water for 20 min.
[0702] Aliquots of 50 μL of loaded plasma (matrix) containing compound 1 or warfarin were transferred in triplicate to the appropriate wells of the sample collection plate. The sample was matched with the dialysis buffer to obtain a final volume of 100 μL with a plasma (matrix): dialysis buffer (1: 1, v: v) volume ratio in each well. The dialysis buffer was 100 mM sodium phosphate and 150 mN NaCl, with a pH of 7.4. Stop solution was added to the time 0 (T0) sample of compound 1 and warfarin. The plate was sealed and vibrated at 800 rpm for 10 min. The T0 sample was then stored at 2-8 ° C.
[0703] Aliquots of 150 μL of loaded plasma (matrix) containing compound 1 or warfarin were transferred to the donor side of each dialysis well in triplicate, and 150 μL of dialysis buffer was loaded to the receiving side of the well. The plate was then rotated at approximately 100 rpm for 4 hours in a humidified incubator at 37±1°C with 5% CO2.
[0704] At the end of dialysis, aliquots of 50 μL of sample from the buffer side and plasma (matrix) side of the dialysis device were transferred to a new 96-well plate (sample collection plate). An equal volume of buffer or plasma was added to each sample well, with a final volume of 100 μL in each well, with a volume ratio of plasma (matrix): dialysis buffer of 1:1 (v:v). All samples were further processed by protein precipitation for LC / MS / MS analysis.
[0705] % Unbound, % Bound, % Yield, and % Remaining were calculated using the following formulas:
[0706] % unbound = 100 x F / T
[0707] % bound = 100 - % unbound
[0708] % yield = 100 × (F + T) / T0
[0709] F = Compound 1 concentration on the receiving side of the membrane / correction factor.
[0710] T = Compound 1 concentration on the donor side of the membrane / correction factor.
[0711] T0 = Compound 1 concentration at time 0 / correction factor.
[0712] Correction factor = aliquot volume / total volume.
[0713] The results are as follows Figure 7 Ascr#7 had unbound percentage values of 86.8% and 94.6% in human and rat plasma, respectively. Compound 1 had an unbound percentage value of 32.9% in human plasma.
[0714] Example 8
[0715] 5-in-1 CYP inhibition assay of compound 1 (1 concentration, n=2)
[0716] CYP450-dependent activities were determined using a marker substrate mixture. For each reaction, enzyme activity in the presence and absence of the test compound (10 μM) was determined in duplicate. A known inhibitor of each isoform tested at a single concentration (3 μM, n=2) was included as a positive control.
[0717] The incubation mixture containing microsomes, substrate and standard inhibitors or test compounds was warmed for 10 minutes at 37° C. The reaction was initiated by the addition of NADPH and incubated for 10 min.
[0718] Table 5.
[0719]
[0720] After incubation, ice-cold acetonitrile was added to terminate the reaction.
[0721] Metabolite generation from substrate reactions was determined by LC-MS / MS.
[0722] The results are as follows Figure 8 Ascr#7 inhibited cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, and 3A4 by 2.3%, 0.0%, 4.0%, 4.6%, and 0.0%, respectively. Compound 1 inhibited cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, and 3A4 by 10.9%, 4.3%, 16.2%, 10.1%, and 1.0%, respectively.
[0723] Example 9
[0724] Identification of metabolites of compound 1 in liver hepatocytes
[0725] The concentration of compound 1 was 10 μM, and 7-ethoxycoumarin at a concentration of 30 μM was used as a positive control. The incubation medium was Williams medium E (without phenol red) containing 2 mM L-glutamine and 25 mM HEPES, and 1.0×10 6 Cryopreserved mouse hepatocytes were seeded in 96-well plates at a density of 10 cells / mL. The total incubation volume in the 96-well plate was 200 μL, and the time points of 0 minutes and 120 minutes were incubated at 37°C, 5% CO2 / 95% humidity, at least in duplicate. Proteins were precipitated with 800 μL of acetonitrile containing 0.1% formic acid and further centrifuged. The supernatant was dried with N2. The residue was reconstituted with 200 μL of 10% acetonitrile containing 0.1% formic acid, and 15 μL was injected into LCMS and analyzed using the following parameters.
[0726] Table 6. LC-MS parameters for metabolite identification in samples
[0727]
[0728]
[0729]
[0730] Table 7. LC-MS parameters of positive control 7-ethoxycoumarin
[0731]
[0732]
[0733]
[0734] MS E : Alternating from low to high collision energy (CE) in QTOF MS provides data-independent (data-rich) profiles. For low CE, (1: TOF MS); for increased CE, (2: TOF MS).
[0735] Example 10
[0736] Efficacy of compound 1 in the animal model of dust mite asthma
[0737] The efficacy of compound 1 was studied in a C57bl / 6 wild-type mouse airway inflammation model using repeated intranasal challenges (acute model, 9 exposures) of the aeroallergen house dust mite (HDM) (D. pteronyssinus). Mice were exposed to 60 μg HDM in 35 μL 1X DPBS (or PBS alone as a control) for 3 consecutive days per week for 3 weeks. The level of eosinophilic airway inflammation was assessed 24 hours after the last HDM (or PBS) challenge by measuring the percentage of eosinophils in bronchoalveolar lavage fluid (BAL) by flow cytometry.
[0738] The HDM intranasal method includes placing the mouse in an isoflurane / O2 chamber until deep breathing, with the oxygen tank set to 1L / min and the isoflurane tank set to 3L / min. 35 μL HDM (or PBS) is applied into the mouse nostrils while gently closing the mouse's mouth to encourage breathing through the nose, thereby assisting HDM delivery to the lungs. The mouse is held upright for 10 seconds, and the mouse is returned to the ISO / O2 chamber for about 2 minutes or until deep breathing is restored. The mouse is held upright for 10 seconds and placed in a recovery cage.
[0739] Bronchoalveolar lavage (BAL) was collected from mice after sacrifice. Briefly, FACS buffer was injected into the lungs through an intratracheal catheter to extract bronchoalveolar cells. Lung tissue was also collected as a tissue cassette embedded in paraffin and fixed with 10% formalin. Lung tissue was stained with hematoxylin and eosin and analyzed for histology.
[0740] BAL cells were counted using 1:10 dilutions of BAL samples in Turks. BAL samples were stained for flow cytometry with a cocktail of antibodies including PE-Cy7CD45, PE-Siglec-F, PE-IgG2a, APC Cd11c, and APC-IgG. All samples were centrifuged at 300xg for 5 minutes at 4°C, and the supernatant was discarded. The cell pellet was resuspended in 40 μL FACS buffer, and 10 μL of each dye was added to 0.4 x 10 6The cells were fixed by incubating the tubes in the dark for 5 minutes. 400 μL FACS buffer was added to each sample and the samples were centrifuged at 300 x g for 5 minutes at 4 °C. The supernatant was discarded and 100 μL 2% paraformaldehyde diluted in FACS buffer was added to the cell pellet in each test tube. The cells were fixed by incubating the test tubes in the dark at room temperature for 5 minutes. 400 μL FACS buffer was added to each sample to dilute the fixative and the samples were centrifuged at 300 x g for 5 minutes at 4 °C. The supernatant was discarded and the cell pellet was resuspended in 400 μL FACS buffer.
[0741] BAL samples were analyzed by flow cytometry. Data can be acquired using a Beckman Gallios flow cytometer using Kaluza software, and the percentage of eosinophils in each sample can be quantified using FlowJo. The percentage of eosinophils in HDM-challenged mice was compared to the percentage of eosinophils in PBS-treated mice. Eosinophils in lung histology were quantified by hematoxylin and eosin staining.
[0742] Embodiment 11
[0743] Stimulation of THP-1 cells: testing the effects 6 or 36 hours after stimulation
[0744] Human immortalized monocytic THP-1 cells were maintained in RPMI 1640 medium without phenol red containing 10% (v / v) fetal bovine serum (FBS), 2 mM L-glutamine, penicillin (100 units / mL), streptomycin (100 units / mL), amphotericin B (2.5 μg / mL) and 50 μM β-mercaptoethanol (BME) at 37°C with 5% (v / v) CO2. THP-1 cells were seeded in 1 mL of THP-1 medium (cell culture medium containing 10% (v / v) FBS, 2 mM L-glutamine, penicillin (100 units / mL), streptomycin (100 units / mL), amphotericin B (2.5 μg / mL) and 50 μM BME) / well in 6-well plates at a density of 1×10 6Cells / ml. By adding 10, 50 or 100nM phorbol 12-myristate 13-acetate (PMA) to each well, then incubating cells at 37°C with 5% (v / v) CO2 for 5.5h, cells are differentiated. Without removing the culture medium, compounds of different concentrations (0, 0.1, 1.0, 10, 100, 200 or 500 μM) are added to each well. Within 30min, cells are stimulated by adding 20ng / mL interferon-γ (IFNγ) and 100ng / mL lipopolysaccharide (LPS) to each well. After stimulation, THP-1 cells are incubated at 37°C and 5% (v / v) CO2 for 6 hours or 36 hours. Supernatant is collected and stored at -80°C until use.
[0745] IL-6 released from supernatants collected 6 or 36 hours after stimulation with IFNγ and LPS was measured using the AlphaLISA Human IL-6 Assay Kit. Fig. 9 Shown is a control representing 0 percent inhibition (stimulated with IFNγ and LPS, but no compound administered), when different concentrations of compounds from 0.1 to 500 μM are applied, relative to the control of IL-6 levels secreted by THP1 derived macrophages. Pretreatment with increasing concentrations of representative compounds 1, 2, 3, 5, 6, 8, 9, 10, 11 and 13 inhibited IL-6 expression in a statistically significant, dose-dependent manner in THP1 human macrophages. Fig. 9 The analogs shown in demonstrated inhibition of IL-6 expression in THP1 cells that was far superior to the blockade observed with NDM-X.
[0746] Example 12
[0747] Stimulation of BEAS-2B human lung epithelial virus-transformed cells: effects of test compounds
[0748] BEAS-2B cells were maintained in bronchial epithelial cell growth basal medium (BEBM), which contains all the recommended supplements for bronchial epithelial cell growth medium (BEGM; Lonza #CC-4175), and allowed to reach approximately 70% confluence at 37°C, 5% (v / v) CO2, with medium changes every 2-3 days. Tissue culture flasks / containers were pre-coated with a mixture of 0.01 mg / mL fibronectin (Sigma), 0.03 mg / mL type I bovine collagen (Sigma), and 0.01 mg / mL bovine serum albumin dissolved in BEBM. BEAS-2B cells were plated in 24-well plates at 1×10 cells / well in 0.5 ml. 6Cells / ml were seeded in BEGM and incubated overnight at 37°C with 5% (v / v) CO2. Cells were pretreated with different concentrations of compounds (0, 1.0, 10, 100, 1000 μM) for 1 hour and then stimulated. To stimulate cells, 10 ng / mL interleukin-1β (IL-1β), 10 ng / mL lipopolysaccharide (LPS) or 20 ng / mL IL-1β were added to the wells without removing the culture medium and incubated at 37°C with 5% (v / v) CO2 for 48 hours. Supernatants were collected and stored at -80°C until quantitative detection analysis was performed.
[0749] UserMagnetic The assay kit measures human eotaxin, monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-25 (IL-25), interleukin-33 (IL-33), thymic stromal lymphopoietin (TSLP), and granulocyte-macrophage colony-stimulating factor (GM-CSF) released from supernatants collected after stimulation. Human CCL5 / RANTES was measured using an enzyme-linked immunosorbent assay (ELISA)-based assay.
[0750] Fig. 10A and 10B , Stimulated (induced with 10 ng / mL IL-1β but not treated with compound) represents 0% inhibition, showing the percentage inhibition of the stimulated group relative to IL-6, IL-8, IL-25, IL-33, eotaxin, GMCSF, MCP-1 and TSLP expression in EPC2 human primary esophageal keratinocytes when induced with 10 ng / mL IL-1β.
[0751] exist Fig. 10A In the present study, NDM-X did not show convincing inhibitory effects on 10 ng / mL IL-1β-induced IL-6, IL-8, and IL-33 expression in BEAS-2B human lung epithelial cells, except for IL-25 expression. Fig. 10A In the study, 100 μM of compound 1 demonstrated statistically significant, complete inhibition of 10 ng / mL IL-1β-induced IL-6, IL-8, IL-25, and IL-33 expression in BEAS-2B human lung epithelial cells. Regarding IL-1β-induced IL-25 expression, NDM-X and compound 1 showed very similar properties, with statistically significant, dose-dependent inhibition.
[0752] exist Fig. 10BIn the present study, NDM-X did not show convincing inhibitory effects on GM-CSF, MCP-1, and TSLP expression stimulated by 10 ng / mL IL-1β in BEAS-2B human lung epithelial cells, except for eotaxin expression. Fig. 10B In the experiment, 100 μM of compound 1 showed statistically significant and complete inhibition of GM-CSF, MCP-1 and TSLP expression. When stimulated with 10 ng / mL IL-1β, NDM-X and compound 1 showed very similar properties in BEAS-2B human lung epithelial cells, with statistically significant and dose-dependent inhibition of eotaxin.
[0753] The stimulated group (induced with 10 ng / mL LPS but not treated with compound) represents zero percent inhibition. Fig.11A and 11B Shown is the percent inhibition of the stimulation group relative to IL-6, IL-8, IL-25, IL-33, eotaxin, GMCSF, MCP-1, and TSLP expression in BEAS-2B human lung epithelial cells when stimulated with 10 ng / mL LPS. Fig.11A In the present study, NDM-X did not show convincing inhibition of 10 ng / mL LPS-induced expression of IL-6, IL-8, IL25, and IL-33 in BEAS-2B human lung epithelial cells. However, compound 1 at 100 μM showed complete and statistically significant inhibition of the expression of multiple inflammatory cytokines. Fig. 11B Although NDM-X did not show convincing inhibitory effects on 10 ng / mL LPS-induced GM-CSF, MCP-1, and TSLP expression in BEAS-2B human lung epithelial cells, statistically significant, complete inhibition of the expression of multiple inflammatory cytokines was observed using 100 μM of compound 1.
[0754] In the same BEAS-2B assay, the stimulated group (induced with 20 ng / mL IL-1β but not treated with compound) represents zero percent inhibition, Fig.12 Shown is the percent inhibition of IL-25, IL-33, eotaxin, and TSLP expression in BEAS-2B human lung epithelial cells when stimulated with 20 ng / mL IL-1β relative to the stimulated group. Fig.12 In the study, a statistically significant inhibition of 20 ng / mL IL-1β-induced IL-33, eotaxin, and TSLP expression was demonstrated in BEAS-2B human lung epithelial cells and this blocking effect was superior to the attenuation observed with NDM-X. Fig.12Compound 6 showed strong inhibition of IL-25 expression at 1 mM concentration, which even peaked at 60% at 100 μM, but NDM-X showed a statistically significant, dose-dependent blocking effect in BEAS-2B human lung epithelial cells induced with 20 ng / mL IL-1β.
[0755] Fig.13 , the stimulated group (induced with 20 ng / mL IL-1β, but not treated with compound) represents zero percent inhibition, the percent inhibition of the stimulated group relative to eotaxin expression in BEAS-2B human lung epithelial cells when stimulated with 20 ng / mL IL-1β. Compound 2, a representative compound, showed statistically significant, complete inhibition of eotaxin induced by 20 ng / mL IL-1β in BEAS-2B human lung epithelial cells, while NDM-X achieved statistically significant, nearly complete blockade at 10 and 100 μM concentrations.
[0756] Example 13
[0757] Stimulation of blood-borne naive T cells with Dermatophagoides Pteronyssinus (house dust mite) antigens: Effects of test compounds
[0758] Naive T cells from peripheral blood samples were collected and used according to the manufacturer's protocol. Whole Blood Pan T Cell Isolation Kit (Miltenyi Biotec) was used to isolate naive T cells. The isolated naive T cells were cultured in RPMI medium supplemented with 5% fetal bovine serum (FBS) at 37°C and 5% (v / v) CO2. T cells were plated at 0.5×10 6 The cells were seeded in 24-well culture plates at a density of 10 cells. The cells were pretreated with compounds (0, 0.1, 1.0, 10, 100 μM) for 1 hour before stimulation. The cells were stimulated with 10 mg / mL of house dust mite (Der p 1) antigen. After 48 hours, fresh 10 mg / mL Der p 1 was added and incubated at 37°C with 5% (v / v) CO2 for another 72 hours. All T cells were stimulated with 10 mg / mL Der p 1 antigen for 5 days, and the supernatant was then collected and stored at -80°C until quantitative detection analysis.
[0759] UserMagnetic The assay kit measures human interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 13 (IL-13), interleukin 23 (IL-23), and interferon gamma (IFNγ) released from supernatants collected after stimulation. Human transforming growth factor beta (TGFβ) was measured using an enzyme-linked immunosorbent assay (ELISA)-based assay.
[0760] Fig.14 The stimulated group (induced with Der p 1 antigen but not treated with compound) represents zero percent inhibition, and the percentage inhibition of the stimulated group relative to IL-5, IFNγ and TGFβ expression in isolated human naive T cells that had been challenged with Der p 1 antigen for 5 days is shown. Fig.14 Compound 1, a representative compound, demonstrated statistically significant, dose-dependent inhibition of multiple inflammatory cytokines such as IL-5, IFNγ, and TGFβ. Fig.14 In the experiment, NDM-X showed a dose-dependent inhibitory effect on IL-5 expression, a statistically significant and strong blocking effect on IFNγ expression, and a mild attenuation effect on TGFβ expression. Fig.14 Compound 1 was shown to inhibit the expression of multiple inflammatory cytokines in a statistically significant, dose-dependent manner that was superior to the blocking effect observed using NDM-X in human T cells challenged with Der p 1 antigen.
[0761] In the same T cell assay, Fig.15 The stimulated group (induced with Der p 1 antigen, but not treated with compound) represents zero percent inhibition, and the percent inhibition of the stimulated group relative to IL-6, IL-8, and TNFα expression is shown. Representative compounds, compound 3 and compound 4, showed statistically significant inhibition of IL-6, IL-8, and TNFα expression at a concentration of 100 μM in human T cells challenged with Der p 1 antigen.
[0762] Embodiment 14
[0763] Stimulation of the A549 human lung cancer cell line: Effects of test compounds
[0764] A549 cells were cultured at 37°C with 5% (v / v) CO2 in DMEM supplemented with 2 mM glutamine and 10% fetal bovine serum (FBS). The cells were grown to approximately 80% confluence before passaging, and the medium was changed every 2-3 days. A549 cells were cultured at 37°C with 5% (v / v) CO2 at 0.5 x 10 6The density of cells / well was seeded in a 24-well plate. These cells were pretreated with compounds (0, 1.0, 10, 100 μM) for 1 hour before adding 10 ng / mL TNFα and human 10 ng / mL IL-1β48 hours at 37°C with 5% (v / v) CO2. The supernatant was collected and stored at -80°C until quantitative detection analysis was performed.
[0765] UserMagnetic The assay kit measures human eotaxin, monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-25 (IL-25), interleukin-33 (IL-33), thymic stromal lymphopoietin (TSLP), and granulocyte macrophage colony stimulating factor (GM-CSF) released from supernatants collected after stimulation. Human CCL5 / RANTES was measured using an enzyme-linked immunosorbent assay (ELISA)-based assay.
[0766] Fig.16 The stimulated group (induced with TNFα and IL-1β, but not treated with compound) represents zero percent inhibition, showing the percent inhibition of the stimulated group relative to IL-8, IL-25, IL-33, MCP-1, and GM-CSF expression when induced with 10 ng / mL TNFα and 10 ng / mL IL-1β for 48 hours in the A549 human lung cancer cell line. Fig.16 Compound 1, a representative compound, demonstrated statistically significant, dose-dependent inhibition of IL-33, MCP-1, and GM-CSF expression induced by TNFα and IL-1β in A549 human alveolar epithelial cells. Fig.16 The percentage inhibition properties exhibited by compound 1 were much better than those exhibited by NDM-X. Although NDM-X did not affect the expression of IL-8 and IL25 induced by TNFα and IL-1β in A549 human alveolar epithelial cells, Fig.16 Compound 1 showed a dose-dependent inhibitory effect.
[0767] The stimulated group (induced with TNFα and IL-1β but not treated with compounds) represents zero percent inhibition, Fig.17 Shown is the percent inhibition of the stimulated group relative to IL-25, IL-33, MCP-1, and GM-CSF expression in human lung cancer cell lines when induced for 48 hours with 10 ng / mL TNFα and 10 ng / mL IL-1β. Fig.17In the present invention, another representative compound, compound 10, demonstrated an overall statistically significant, dose-dependent inhibitory effect on the expression of multiple inflammatory cytokines including IL-25, IL-33, MCP-1, and GM-CSF in the A549 human lung cancer cell line when induced with TNFα and IL-1β, which was superior to NDM-X blockade. However, NDM-X showed a statistically significant but non-dose-dependent inhibitory effect on the expression of MCP-1 and GM-CSF induced by TNFα and IL-1β.
[0768] Fig.18 The stimulated group (induced with TNFα and IL-1β, but not treated with compound) represents zero percent inhibition, showing the percent inhibition of the stimulated group relative to eotaxin, IL-6, RANTES, and TSLP expression in the human A549 lung cancer cell line when induced with 10 ng / mL TNFα and 10 ng / mL IL-1β for 48 hours. Fig.18 Among them, both representative compounds, Compound 1 and Compound 10, demonstrated strong, statistically significant inhibitory effects on TNFα- and IL-1β-induced eotaxin, IL-6, RANTES, and TSLP expression in A549 human alveolar epithelial cells.
[0769] Embodiment 15
[0770] Stimulation of EPC2-hTERT immortalized human esophageal keratinocytes:
[0771] Effects of test compounds
[0772] EPC2-hTERT (EPC2) cells were maintained in keratinocyte-supplemented serum-free medium (KSFM) containing 0.09 mM calcium chloride, epidermal growth factor (5 ng / mL), bovine pituitary extract (50 mg / mL), penicillin (100 units / mL) and streptomycin (100 mg / mL) (ThermoFisher #17005042) at 37°C and 5% (v / v) CO2. EPC2 cells were cultured at 0.55×10 per well at 37°C and 5% (v / v) CO2. 6Cells were seeded in 12-well plates, and the old culture medium was removed and replaced with fresh culture medium after 6 hours. After overnight incubation, the old culture medium was replaced with KSFM supplemented with 1.8mM calcium chloride and incubated for 72 hours at 37°C with 5% (v / v) CO2. After removing the old culture medium and adding freshly supplemented KSFM containing 1.8mM calcium chloride, cells were pretreated with different concentrations of compounds (0, 1, 10, 100, 500, 1000 μM) for 1 hour before stimulation. In order to stimulate cells, poly (I: C) (Tocris #4287) was added to the wells at a concentration of 10 mg / mL without removing the culture medium, and incubated for 24 hours at 37°C with 5% (v / v) CO2. The supernatant was collected in an Ependorf tube, centrifuged in a microcentrifuge at maximum speed for 10 minutes at 4°C, and the centrifuged supernatant was stored at -80°C until quantitative detection analysis was performed.
[0773] Human interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and thymic stromal lymphopoietin (TSLP) released from the stimulated supernatant were measured using AlphaLISA assay kits for human IL-6, MCP-1, and TSLP, respectively.
[0774] Human TSLP released from supernatants collected 24 hours after stimulation with poly(I:C) was measured using the AlphaLISA Human TSLP Detection Kit. The stimulated group (induced with poly(I:C) but not treated with compound) represents zero percent inhibition, Fig.19A The percentage inhibition of TSLP expression in EPC2 human primary esophageal keratinocytes relative to the stimulated group is shown. Pretreatment with increasing concentrations of representative compounds 1, 3, 4, and 10 showed a statistically significant inhibitory effect on the inhibition of TSLP expression in EPC2 human primary esophageal keratinocytes induced by poly(I:C). Fig.19A In EPC2 human primary esophageal keratinocytes, while compounds 1, 10, and 13 showed strong blocking, compounds 3 and 4 completely inhibited TSLP expression induced by poly(I:C).
[0775] Human IL-6 released from supernatants collected 24 hours after stimulation with poly(I:C) was measured using the AlphaLISA Human IL-6 Detection Kit. Fig.19B, the stimulated group (induced with poly(I:C) but not treated with compound) represents zero percent inhibition, showing the percent inhibition of the stimulated group relative to IL-6 expression in EPC2 human primary esophageal keratinocytes. Pretreatment with increasing concentrations of representative compounds Compounds 1, 3, 4, and 10 inhibited IL-6 expression in a statistically significant, dose-dependent manner in human primary esophageal keratinocytes (EPC2) when stimulated with poly(I:C). Fig.19B Compound 2 showed a strong inhibitory effect on IL-6 expression at a concentration of 100 μM.
[0776] Human MCP-1 released from supernatants collected 24 hours after stimulation with poly(I:C) was measured using the AlphaLISA Human MCP-1 Assay Kit. The stimulated group (induced with poly(I:C) but not treated with compound) represents zero percent inhibition, Fig.19C The percentage inhibition of the stimulation group relative to MCP-1 expression in EPC2 human primary esophageal keratinocytes is shown. Pretreatment with increasing concentrations of representative compounds Compounds 1, 3, 10 and 11 inhibited MCP-1 expression in a statistically significant, dose-dependent manner in human primary esophageal keratinocytes (EPC2) when stimulated with poly(I:C). Fig.19C In the assay, although compound 13 showed a strong blockade of MCP-1 expression starting from 1 mM, compound 2 and compound 4 exhibited an inhibitory effect only at a concentration as high as 100 μM.
[0777] Example 16
[0778] Induction of eosinophilic esophagitis (EoE) in a mouse model: effects of test compounds
[0779] Eosinophilic esophagitis (EoE) is a chronic allergic gastrointestinal disease caused by a hypersensitivity reaction of the esophageal mucosa and manifests as dysphagia and food impaction in adults and symptoms previously associated with gastroesophageal reflux disease in children.
[0780] Based on the observation of increased local expression of interleukin-5 (IL-5) in EoE, transgenic mice with targeted IL-5 expression to the esophageal squamous epithelium using the Epstein-Barr virus ED-L2 (EBV-ED-L2) gene promoter were generated. The transgenic mice showed constitutive squamous esophageal epithelium-specific overexpression of IL-5 (L2-IL5 transgenic mice) and resulted in baseline esophageal eosinophilia. Even though squamous epithelium-specific IL-5 expression alone induced significant esophageal eosinophilia encompassing the length of the esophagus, this eosinophilia was not accompanied by changes in histopathological density, such as eosinophilic microabscesses characteristic of EoE. However, L2-IL5 transgenic mice developed key histopathological features upon sensitization and subsequent localized esophageal challenge with 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (OXA), a molecule known to induce T helper (Th) type 2 responses, including epithelial hyperplasia and eosinophilic microabscesses that protrude through the epithelium into the esophageal lumen. Immunohistochemical staining for eosinophil secondary granule major basic protein (MBP-1) was used to assess induced esophageal eosinophilia and eosinophil degranulation. Immunohistochemical evaluation in wild-type mice showed that vehicle showed no tissue eosinophilia, although OXA treatment showed mild tissue eosinophilia. In L2-IL5 transgenic mice, vehicle-treated mice showed statistically higher eosinophilia than that observed in wild-type animals. However, this response was small compared to the induced eosinophilia and associated degranulation seen in OXA-treated L2-IL5 transgenic mice (Masterson et al. Gut. 2014, 63, 1-25, incorporated herein by reference in its entirety).
[0781] Prior to the OXA sensitization and localized challenge model of delayed contact hypersensitivity, L2-IL5 transgenic mice were injected intraperitoneally (IP) with compound or vehicle ( Fig. 20Protocol timeline in A). Compounds were prepared as master stocks by dissolving in dimethyl sulfoxide (DMSO). Fresh working compound stock aqueous solutions were prepared each injection day, and 100 μL of working stock solution or vehicle was injected IP per mouse. On day 0 of OXA sensitization / local challenge, a 2 cm×2 cm abdominal skin area of anesthetized experimental animals was shaved and OXA was applied to the skin surface (150 μl of 3% (w / v) OXA in 4:1 acetone-olive oil medium) to initiate the sensitization phase of the protocol. Sensitized mice were then subjected to local OXA challenges of the esophagus by gavage on days 5, 8, and 12 of the protocol after OXA sensitization with 100 μL of 1% (w / v) OXA in 30% ethanol / olive oil medium into the proximal esophagus. In addition, compounds or vehicle were injected IP on days 5, 8, and 12 after OXA sensitization. 24 hours after the last OXA challenge on day 12, all mice were sacrificed and the esophagus was harvested for histology ( Fig. 20 A). Immunohistological staining using a rat monoclonal anti-mouse MBP-1 antibody was performed to highlight esophageal eosinophilic infiltration and focal degranulation. Quantitative assessment of esophageal eosinophilic infiltration in each group of mice was determined in nine high-power fields (hpf), three distal (located closer to the mouth (Dis)), three mid (Mid), and three proximal (located closer to the stomach (Prox)) regions and expressed as group mean data of eosinophil density (i.e., eosinophils / 400×hpf) ( Fig. 20 B). In addition, eosinophilia was recorded in the different cell layers of the esophagus (epithelial, lamina propria, and muscle) ( Fig. 20 C). These data are representative of separate experiments with 3 to 9 individual mice per group (*p≤0.05, **p≤0.001. ***p≤0.0001) (Masterson et al. Gut. 2014, 63, 1-25).
[0782] Prior to the OXA sensitization and localized challenge model of delayed contact hypersensitivity, L2-IL5 transgenic mice were injected intraperitoneally (IP) with a high dose of NDM-X at 19.2 μg / mouse (assuming 25.0 g mice = 0.77 mg / kg), a high dose of Compound 1 at 23.1 μg / mouse (assuming 25.0 g mice = 0.92 mg / kg), or vehicle ( Fig. 20The compounds were prepared by dissolving in dimethyl sulfoxide (DMSO) to prepare high-dose parent stock solutions at a concentration of 9.6 μg / μL for NDM-X and 11.54 μg / μL for compound 1. For each injection cohort, which was used to IP inject 100 μL of working stock solutions NDM-X high dose and compound 1 high dose per mouse, fresh high-dose working stock solutions of 0.192 μg / μL NDM-X in water (20 μL parent stock solution in 980 μL water) and 0.231 μg / μL compound 1 in water (22 μL parent stock solution in 1078 μL water) were prepared, respectively. On day 0 of OXA sensitization / topical challenge, a 2 cm×2 cm abdominal skin area of anesthetized experimental animals was shaved, and OXA was applied to the skin surface to initiate the sensitization phase of the protocol. Sensitized mice then received local OXA challenge in the proximal esophagus by gavage on days 5, 8, and 12 of the post-OXA sensitization protocol. In addition, compound or vehicle was injected IP on days 5, 8, and 12 after OXA sensitization.
[0783] Fig.21 Shown are high-power magnification microscopic images using MBP-1 immunohistochemical staining of mouse esophagus for quantitative assessment of eosinophilic esophagitis on day 13 after sensitization and localized challenge with OXA in the IL2-IL5 transgenic mouse model. Fig.21 It was shown that the high dose of 0.92 mg / kg Compound 1 exhibited a statistically significant inhibitory effect on eosinophilic esophagitis in the epithelium, lamina propria, and muscularis of the distal, middle, and proximal cell layers of the esophagus, which resulted in a statistically significant attenuation of eosinophilia in all cell layers of the distal, middle, and proximal regions of the esophagus. Fig.21 In the present invention, 0.77mg / kg NDM-X high dose shows the statistically significant alleviation of eosinophilia in the lamina propria and the myocyte layer in the distal, middle and proximal regions of the esophagus, which causes the statistically significant weakening of eosinophilia in all cell layers in the distal and middle regions of the esophagus. In general, compared with the 0.77mg / kg NDM-X high dose group, 0.92mg / kg compound 1 high dose shows a stronger blocking effect on eosinophilic esophagitis in the mouse model. This comparative trend remains true, except for the eosinophilia in the myocyte layer in the distal region of the esophagus, wherein 0.77mg / kg NDM-X high dose shows a slightly better blocking of eosinophilia than 0.92mg / kg compound 1 high dose, but both are statistically significant. These data represent the experiment of 6 to 7 individual mice in each group (*p≤0.05, **p≤0.001.***p≤0.0001).
[0784] Prior to the OXA sensitization and localized challenge model of delayed contact hypersensitivity, L2-IL5 transgenic mice were injected intraperitoneally (IP) with a low dose of NDM-X at 0.30 μg / mouse (assuming 25.0 g mice = 0.012 mg / kg), a low dose of Compound 1 at 0.36 μg / mouse (assuming 25.0 g mice = 0.014 mg / kg), or vehicle ( Fig. 20 A protocol timeline). Low-dose master stock solutions were prepared by dissolving NDM-X and compound 1 in dimethyl sulfoxide (DMSO) to make 0.50 μg / μL NDM-X and 0.58 μg / μL compound 1. To prepare fresh working stock solutions, the master stock solutions were diluted with water to make 0.003 μg / μL NDM-X working stock solution and 0.0036 μg / μL compound 1 working stock solution, which were used for IP injection of 100 μL / mouse NDM-X low dose and compound 1 low dose, respectively.
[0785] Fig. 22 Shown are high-power magnification microscopy images of MBP-1 immunohistochemical staining of mouse esophagus, quantitatively assessed for eosinophilic esophagitis at day 13 after sensitization and localized OXA challenge in the IL2-IL5 transgenic mouse model. In contrast to the superior inhibition of eosinophilia by high dose of 0.92 mg / kg Compound 1 compared to high dose of 0.77 mg / kg NDM-X, comparable blockade of eosinophilia was demonstrated using low dose of 0.014 mg / kg Compound 1 and low dose of 0.012 mg / kg NDM-X in the OXA sensitization and localized challenge model of delayed contact allergy in L2-IL5 transgenic mice. Fig. 22 In the present invention, the low dose of 0.014 mg / kg compound 1 showed a statistically significant inhibitory effect on the eosinophilia in all cell layers of the proximal zone of the esophagus, the epithelial cell layer of the distal zone, and the lamina propria cell layer of the middle part, which resulted in a statistically significant blockade of the eosinophilia in all cell layers of the middle, proximal, and entire tissues of the esophagus. On the other hand, the low dose of 0.012 mg / kg NDM-X showed a statistically significant inhibitory effect on the eosinophilia in all cell layers of the proximal zone, the muscle cell layer in all regions, and the epithelial cell layer in the distal and proximal zones, which resulted in a statistically significant attenuation of the eosinophilia in all cell layers of all zones in the esophageal OXA sensitization and localized challenge models of delayed contact hypersensitivity in the L2-IL5 transgenic mouse model.
[0786] Prior to the OXA sensitization and localized challenge model of delayed contact hypersensitivity, L2-IL5 transgenic mice were injected intraperitoneally (IP) with 2.31 μg / mouse (assuming 25.0 g mouse = 0.092 mg / kg) of the medium dose, 23.1 μg / mouse (assuming 25.0 g mouse = 0.92 mg / kg) of the high dose, or vehicle ( Fig. 20 A protocol timeline). A stock solution was prepared by dissolving 24.8 mg of Compound 1 in 214.6 μL dimethyl sulfoxide (DMSO) to make a 115.6 μg / μL stock solution of Compound 1. 30 μL of the Compound 1 stock solution was further diluted with 270 μL DMSO to make a 11.56 μg / μL stock solution Compound 1 high dose, and 20 μL of the Compound 1 high dose was further diluted with 180 μL DMSO to make a 1.16 μg / μL stock solution Compound 1 medium dose. To prepare fresh working stock solution, 25 μL of the mother stock solution of Compound 1 low dose and the mother stock solution of Compound 1 high dose were mixed with 1225 μL of water to make the working stock solution of Compound 1 medium dose (0.0231 μg / μL) and the working stock solution of Compound 1 high dose (0.231 μg / μL), respectively, which were used for IP injection of 100 μL / mouse of the medium dose and high dose of Compound 1, respectively.
[0787] Fig.23 Shown are high-power magnification microscopic images using MBP-1 immunohistochemical staining of mouse esophagus for quantitative assessment of eosinophilic esophagitis on day 13 after sensitization and localized challenge with OXA in the IL2-IL5 transgenic mouse model.
[0788] exist Fig.23 In the present invention, pretreatment with a high dose of 0.92 mg / kg of compound 1 by IP injection resulted in a statistically significant inhibition of eosinophilic esophagitis observed in the epithelial cell layer of the distal, middle and proximal regions of the esophagus. In addition, a high dose of 0.92 mg / kg of compound 1 showed a statistically significant inhibitory effect on the eosinophilia observed in the lamina propria and muscle cell layer of the middle esophagus. The same high dose of compound 1 confirmed the statistically significant reduction of eosinophilia observed in all cell layers of the middle and proximal segments and the entire esophagus.
[0789] Overall, Fig.23 It was shown that pretreatment with IP injection of 0.092 mg / kg medium dose and 0.92 mg / kg high dose of compound 1 inhibited eosinophilia in the epithelium, lamina propria and muscular cell layer of the distal, middle and proximal regions of the esophagus in a dose-dependent manner. These data represent experiments of 8 to 9 individual mice per group (*p≤0.05, **p≤0.001. ***p≤0.0001).
[0790] Prior to the OXA sensitization and localized challenge model of delayed contact hypersensitivity, L2-IL5 transgenic mice were injected intraperitoneally (IP) with 0.3 μg / mouse (assuming 25.0 g mice = 0.012 mg / kg), 19.2 μg / mouse (assuming 25.0 g mice = 0.77 mg / kg), or vehicle ( Fig. 20 A protocol timeline). The stock solutions were prepared by dissolving NDM-X in dimethyl sulfoxide (DMSO) to make 0.5 μg / μL stock solution NDM-X low dose and 9.9 μg / μL stock solution NDM-X high dose. To prepare fresh working stocks, the stock solution NDM-X low dose was diluted with water to prepare 0.003 μg / μL working stock solution NDM-X low dose, and the stock solution NDM-X high dose was diluted with water to prepare 0.192 μg / μL working stock solution NDM-X high dose, which were used for IP injection of 100 microliters / mouse low dose and high dose of NDM-X, respectively.
[0791] Fig.24 Shown in Figure 5 are high-powered microscopic images of MBP immunohistochemical staining of mouse esophagus, quantitative assessment of eosinophilic esophagitis on day 13 after sensitization and localized challenge with OXA in the IL2-IL5 transgenic mouse model. Fig.24 It was shown that there was a huge increase in the eosinophilia observed in IL2-IL5 transgenic mice sensitized with OXA and locally or locally challenged (OXA control) compared to IL2-IL5 transgenic mice not sensitized with OXA and locally or locally challenged (OXA control without). The overall trend showed that the low dose of NDM-X at 0.012 mg / kg was slightly better than the high dose of NDM-X at 0.77 mg / kg in suppressing the eosinophilia observed in the epithelium, lamina propria, and muscle cell layer in the distal, middle, and proximal regions of the esophagus. However, in the epithelium, lamina propria, and all cell layers (except the muscle layer) in the distal region of the esophagus, the high dose of 0.77 mg / kg showed a statistically significant reduction in eosinophilia in a manner slightly better than the low dose of NDM-X at 0.012 mg / kg.
[0792] Fig.24The NDM-X of 0.012mg / kg low dose showed statistically significant inhibition of eosinophilia observed in the epithelium, lamina propria and muscle cell layer of the distal, middle and proximal regions of the esophagus, which resulted in statistically significant weakening of eosinophilia in all cell layers from the distal end of the esophagus to the proximal region. The NDM-X of 0.77mg / kg high dose was shown in statistically significant alleviation of eosinophilia in the epithelium and lamina propria cell layers of the distal, middle and proximal regions of the esophagus, which resulted in statistically significant weakening of eosinophilia in all cell layers from the distal end of the esophagus to the proximal region. These data represent two to three experiments of 3 to 9 individual mice per group (*p≤0.05, **p≤0.001.***p≤0.0001).
[0793] Using the protocols described in Examples 3-16, any other compounds of Table 3 were tested and had similar activities to the compounds tested above.
[0794] Embodiment 17
[0795] Efficacy in IBD Animal Models
[0796] A T cell transfer model of colitis was used in which 500,000 CD4+CD45RBhi cells were transferred into adult Rag1- / - mice. Vehicle or 300 ng of any of compounds 1-56 was administered by intraperitoneal injection at multiple time points each week for 30 days. On day 30, mice were euthanized and colon analysis was performed. T cell activation and phenotype were also analyzed. Normal mouse colons are long, cortical, and have discrete fecal pellets. The colons of diseased mice with IBD have shortened, distended colons with diarrhea instead of discrete fecal pellets.
[0797] Embodiment 18
[0798] Efficacy in EoE Animal Models
[0799] The EoE mouse model induces eosinophilia in oxazolone-sensitized and challenged L2-IL5 mice.
[0800] PL2+ mice were administered intraperitoneal injections of vehicle or any of the compounds 1-56 at different time points, followed by skin sensitization with oxazolone and intraperitoneal injections of vehicle or different concentrations of the compounds). A 2 cm x 2 cm area of the abdominal skin of anesthetized mice was shaved, and oxazolone was applied to the skin surface (150 μL of a 3% (w / v) oxazolone solution in a 4:1 acetone-olive oil medium to initiate the sensitization period). The esophagus was challenged by gavage (i.e.) into the proximal esophagus with a 2% (w / v) oxazolone solution in a 30% ethanol / olive oil medium and intraperitoneal injections of vehicle (100 μL) or different concentrations of the compounds on the following days, and either solvent (100 μL) or different concentrations of the compounds were injected intraperitoneally on the following days. At the completion of the experiment, the mice were euthanized and the esophagus analyzed. The esophagus was embedded in paraffin and fixed on a slide. Esophageal samples were stained according to the MBP IHC protocol, and the distal, mid, and proximal esophagus were analyzed. Eosinophils were counted on MBP-stained esophageal sections.
[0801] Embodiment 19
[0802] Effects in human esophageal cells in vitro
[0803] The effect of any of Compounds 1-56 on CCL26 secretion from epithelial human telomerase reverse transcriptase (EPC-hTERT) cells can be studied.
[0804] Epithelial human telomerase reverse transcriptase EPC2 hTERT cells were cultured in keratinocyte SFM (KSFM) medium containing penicillin (100 units / mL) and streptomycin (100 μg / mL) at 37°C with 5% (v / v) CO2. EPC2-hTERT cells were plated at 0.09 x 10 6 The density of cells / well was seeded in three 24-well plates. The medium was changed about 4 hours after seeding. 24 hours after seeding, the medium was changed to include DI medium and several concentrations of compounds), containing IL-13 and without IL-13. The supernatant was collected, and at several time points after treatment, cells were harvested by adding 350 μL RLT+BME (10 μL BME per 1 mL RLT) in each well. RNA was extracted using Qiagen's Qiashredder and RNeasy kits according to the manufacturer's instructions. cDNA was prepared using a high-capacity cDNA reverse transcription kit. qPCR was run using TaqMan primers and TaqMan FastAdvanced Master Mix.
[0805] Equivalent solutions
[0806] The various methods and techniques described above provide a variety of ways to implement the present invention. Of course, it should be understood that all the objects or advantages described may not necessarily be achieved according to any particular embodiment described in the application. Therefore, for example, it will be appreciated by those skilled in the art that the method may be implemented in a manner that realizes or optimizes one or a group of advantages taught by the application, without having to realize or indicate other objects or advantages taught by the application. The application mentions different favorable and unfavorable alternatives. It should be understood that some preferred embodiments specifically include one, another or several favorable features, while others specifically exclude one, another or several unfavorable features, while some others specifically reduce current unfavorable features by including one, another or several favorable features.
[0807] In addition, those skilled in the art will recognize the applicability of various features from different embodiments. Similarly, the various elements, features and steps discussed above, and other known equivalents of each such element, feature or step can be mixed and matched by those skilled in the art so that those skilled in the art implement the method according to the principles described in the application. Among the various elements, features and steps, some will be specifically included, while others will be specifically excluded in different embodiments.
[0808] While the invention has been disclosed in the context of certain embodiments and examples, those skilled in the art will appreciate that embodiments of the invention extend beyond the specifically disclosed embodiments to other alternative embodiments and / or uses and variations and equivalents thereof.
[0809] Many variations and alternative elements have been disclosed in the embodiments of the present invention. Further variations and alternative elements will be apparent to those skilled in the art. Among these variations, but not limited to, are the selection of the building blocks of the compositions of the present invention and the diseases and other clinical conditions that can be diagnosed, predicted or treated with them.
[0810] In some embodiments, the numerals representing the number of components, properties such as concentration, reaction conditions, etc., used to describe and claim certain embodiments of the present invention should be understood to be modified by the term "about" in some cases. Therefore, in some embodiments, the numerical parameters cited in the written specification and the appended claims are approximate values, which can be varied according to the desired characteristics sought to be obtained in a particular embodiment. In some embodiments, the numerical parameters should be based on the number of significant figures reported and by applying common rounding techniques. Although the numerical ranges and parameters of the wide range of some embodiments of the present invention are approximate values, the numerical values cited in the specific examples are reported as accurately as possible. The numerical values presented in some embodiments of the present invention may include certain errors, which are necessarily the standard deviations found in their respective test measurements.
[0811] In some embodiments, the terms "a" and "an" and "the" and similar reference words used in the context of describing a specific embodiment of the present invention (especially in the context of some of the following claims) can be interpreted as covering singular and plural. The application's reference to a numerical range is only used as a shorthand method for citing each individual value falling within the range individually. Unless otherwise indicated in the application, each individual value is incorporated into this specification as if quoted individually in the application. All methods described in this application can be carried out in any suitable order, except where otherwise specified in the application or clearly contradictory to the context. The use of any and all embodiments or example language (such as "for example") provided for some embodiments in the application is intended only to better illustrate the present invention, and does not limit the scope of the present invention, otherwise protection is required. Any language in this specification should not be interpreted as indicating any unclaimed element essential to the implementation of the present invention.
[0812] The grouping of alternative elements of the present invention disclosed in the present application or embodiments should not be construed as restrictive. Each group member can be mentioned and claimed individually or in any combination with other members of the group or other elements found in the present application. For convenience and / or patentability reasons, one or more group members may be included in a group or deleted from a group. When any such inclusion or deletion occurs, the specification of the present application is deemed to include the modified group, thereby satisfying the written description of all Markush groups used in the appended claims.
[0813] Incorporated by Reference
[0814] All publications of this application are incorporated by reference into this application, just as each individual publication or patent application is specifically and individually indicated as being incorporated by reference. The following description includes information that may be helpful in understanding the present invention. It is not admitted that any information provided in this application is prior art or relevant to the invention currently claimed, or that any publication involved is explicitly or implicitly prior art.
Claims
1. A compound having the structure of formula (I): in Ring D is represents the point of attachment of ring D to the oxygen atom; X is -C(R 5 ) 2 -C(R 5 ) 2 - or is E or Z-CH=CH-; Y is O; R is H or CH 3 , R 1 H or CH 3 ; R 2 H or CH 3 ; R 3 H or CH 3 ; R 4 CH 3 , CH 2 CH 3 Or straight chain or branched chain C 3 -C 6 alkyl; and R 5 Each instance is independently H or OH.
2. The compound of claim 1, wherein X is -C(R 5 ) 2 -C(R 5 ) 2 -.
3. The compound of claim 1, wherein X is E or Z-CH=CH-.
4. The compound according to any one of claims 1 to 3, wherein R 2 is H; and R 4 CH 3 or CH 2 CH 3 .
5. The compound according to any one of claims 1 to 3, wherein R 2 , R 3 and R 4 Each is CH 3 .
6. The compound of claim 1, wherein the compound is selected from 7. The compound of claim 5, wherein the compound is selected from 8. The compound of claim 1, wherein the compound has the structure of formula (II): in A double bond or a single bond.
9. The compound of claim 8, wherein the compound has the structure:
10. The compound of claim 8, wherein the compound has the following structure:
11. The compound of claim 8, wherein the compound is selected from 12. A pharmaceutical preparation comprising a pharmaceutically acceptable carrier; and a compound having the compound structure of any one of claims 1 to 11.
13. Use of a compound according to any one of claims 1 to 11 in the preparation of a medicament for treating eosinophilic esophagitis.
14. The use of claim 13, wherein the prepared medicament further comprises a steroid.
15. The use according to claim 14, wherein the steroid is dexamethasone.
